Podcasts about Clonidine

In this episode of The Poison Lab, host Ryan Feldman is joined by Dr. Amy Zosel, a medical toxicologist, emergency physician, and educator. Together, they use real poisoning cases to practice identifying toxins and flexing their toxic differential The conversation dives into intriguing and challenging toxicology cases, with a focus on educating listeners about real-world poisoning scenarios, myth-busting internet misinformation, and providing practical clinical insights. Mini episode with Dr. Robert Bassett on Remembering Poisonous Mushrooms Dr. Zosel and Ryan discuss:14:15 Case 1 33:04 Case 2News story37:00 Case 3 New story48:00 Case 4 News storyUS outbreak "Robocough"Study about Naloxone in Clonidine overdose++Spoiler++: Below this will be key takeaways regarding managing the poisonings discussed, it may ruin your experience if you are guessing the poisons Key Takeaways:Amatoxin Mushroom Poisoning: The classic delayed onset of severe GI symptoms, followed by a latent phase, can mask progressive liver damage. Early recognition and treatment with hydration, silibinin, and possible liver transplant are critical.Tetramine Toxicity: Known for causing refractory seizures, tetramine is a rare but serious poisoning often requiring aggressive supportive care and anticonvulsants.A Lethal mushroom hiding in edible mushrooms Mushroom foraging dangerResources Mentioned:National Poison Control Hotline: 1-800-222-1222National Suicide Prevention Lifeline: 1-800-273-8255SAMHSA Free Helpline: 1-800-662-HELP (4357)Follow The Poison Lab:Twitter: @LabPoisonInstagram: @tox_talkWebsite: www.ThePoisonLab.comSubscribe and Review:Love what you're hearing? Help us reach more toxicology enthusiasts by leaving a review on Apple Podcasts, Spotify, or wherever you listen. Don't forget to share this episode with...

My guest is Dr. John Kruse, M.D., Ph.D., a psychiatrist specializing in treating people with attention-deficit/hyperactivity disorder (ADHD). We discuss the many stimulant and nonstimulant ADHD medications available, covering both their potential benefits and risks. We also explore behavioral approaches to managing ADHD, the key role of maintaining a consistent sleep-wake schedule, and the impact of exercise, fish oil supplementation, and video games on ADHD. Additionally, we examine the genetic and environmental factors contributing to the rise in adult and child ADHD diagnoses and offer various options to consider if you or someone you know is struggling with focus. Read the full episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman Eight Sleep: https://eightsleep.com/huberman Joovv: https://joovv.com/huberman LMNT: https://drinklmnt.com/huberman Mateina: https://drinkmateina.com/huberman Timestamps 00:00:00 Dr. John Kruse 00:02:11 Attention-Deficit/Hyperactivity Disorder (ADHD) 00:05:37 Genetics & Environment; COVID Pandemic & ADHD Diagnoses 00:11:43 Sponsors: Eight Sleep & Joovv 00:14:26 ADHD, Interest & Careers 00:20:40 Social Media & Distractibility; ADHD & Lifespan Effect 00:27:39 Hyperfocus, Flow States 00:33:45 Tools: 4 Essential Behaviors for ADHD; Regular Meal Schedule 00:41:06 Sponsor: AG1 00:42:21 Tool: Regular Sleep Timing; Stimulants & Sleep 00:48:06 Insomnia; Tools: Bedtime Structure, Exercise, Phones, Breathing 00:52:30 Nighttime Waking Up; Cyclic Sighing 00:56:35 Exercise; Addiction, Risk, Kids & Stimulants; Catecholamines & Focus 01:04:32 Ritalin, Stimulants, Amphetamines; Amphetamine-Induced Psychosis & Risks 01:16:46 Sponsor: LMNT 01:18:03 Adult ADHD & Medications; Stimulants & Cardiovascular Risk? 01:26:06 Adult ADHD Medication Choices, Psychosis, Cannabis 01:33:49 ADHD Symptoms, Nicotine; Caffeine, Energy Drinks, L-Theanine 01:43:28 Fish Oil, Cardiac Effects & ADHD, Tool: Fish Oil Dose, EPA vs DHA 01:49:38 Sponsor: Mateina 01:51:04 Gut Microbiome 01:52:56 ADHD & Cognitive Behavioral Therapy (CBT), Tool: Task List System 01:57:52 Video Games, Neurofeedback, ADHD Benefit?, Tool: Technology Restriction 02:02:26 Guanfacine, Clonidine, Hypertension, Effects & Timeframe 02:10:13 Modafinil, History & Forms, Dependence 02:19:02 Drug Holidays; Short- vs Long-Acting Drugs, Addiction, Vyvanse 02:28:56 Time Perception, ADHD, Circadian Rhythm Disruption, Phototherapy 02:35:39 Zero-Cost Support, YouTube, Spotify & Apple Follow & Reviews, Sponsors, YouTube Feedback, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures

Send us a textClonidine as Monotherapy for Neonatal Opioid Withdrawal Syndrome: A Randomized Trial.Bada HS, Westgate PM, Sithisarn T, Yolton K, Charnigo R, Pourcyrous M, Tang F, Gibson J, Shearer-Miller J, Giannone P, Leggas M.Pediatrics. 2024 Oct 15:e2023065610. doi: 10.1542/peds.2023-065610. Online ahead of print.PMID: 39403061As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

In this episode, Kathleen Page, MD, and Glenn J. Treisman, MD, PhD, discuss the interplay between addiction and HIV. Learn as they share their approaches to reframing the conversation about addiction and overcoming barriers to effective addiction care for people living with HIV.Presenters:Kathleen Page, MDProfessorInfectious DiseasesJohns Hopkins School of MedicineBaltimore, Maryland Glenn J. Treisman, MD, PhDEugene Meyer III Professor of Psychiatry and MedicineJohns Hopkins University School of MedicineBaltimore, MarylandDownloadable slides:https://bit.ly/3TR3OVVProgram:https://bit.ly/3WB2VCO

How do you remember what you need to do for the people you need to do it for, I mean really? Information management is the organization that will allow you to make informed decisions for the people, appointments, and processes in your life. The Sunday Basket® takes care of active papers, but some papers you need to hang on to. There are no more actions to do with this type of paper, but they are critical for future reference. I have a binder system, within The Paper Solution, to help you manage all the informational papers. Medical Binder The Medical Binder has allowed me to have many informed conversations with doctors that have led to not needing tests they may have required otherwise or access to medications the doctor may not have considered. I wanted to try to go on Clonidine to help with my hot flashes due to a hunch I had. I had my medical history with me in my Medical Binder. You know why I had it with me? My doctor does not digitize my records. So there aren't multiple medical records “talking to each other” or being updated. Being prepared for conversations with your doctor can elevate your conversations and the consideration your doctor gives to your concerns or desires. This worked to my advantage many times with my children as well while we tried to get them on a diet and medication that helped them to function their best. With the Medical Binder in hand, you can make critical decisions before you leave the hospital allowing you the best treatment. Let me tell you, you leave the hospital and change your mind? Your options are drastically different with higher price tags. This binder is a life saver! Household Reference Binder When we went to Europe, our smoke detectors went off. And Abby was going crazy so she called grandma, who called Joey. Joey really didn't want to call us. But it ended up being an easy fix due to the Household Reference Binder. Had I not filled it out, there would have been a couple of annoying days or some expensive invoice from ADT to come out and change the batteries. The Household Reference Binder can also remind you when routine maintenance is due and where you can keep appliance user manuals. This binder can also work to your benefit in selling your house - interested buyers will have peace of mind investing in your home when they know you took care of it and that there's a binder to help them take care of their new home.  Financial Binder We just talked about being the CFO of your home. The Financial Binder helps to organize all the financial aspects of your household economy. You can file away all your insurance documents as well as taxes in this binder for quick future reference. I have shared before that I file taxes for Abby and Joey. So this is where I store their license numbers, issue date, and expiration date to save me time when filing their taxes. I don't need it any other time of the year so it goes in this binder. This becomes a valuable binder when it comes to settling an owner's estate. This shaves so many billable hours off an attorney and saves you time, too! Household Operations Binder How does your home function on a yearly cadence? The Household Operations Binder is like your family's standard operating procedures (SOP's.) You may find papers from this binder go into “active status” in the Sunday Basket® for a season and back to the Household Operations Binder until the next time. These papers remind us of facts about holidays or annual events. This binder is also where your family could find information and complete tasks normally they could not because it would all be in your brain. But because of the Household Operations Binder, you have externalized the process thus lowering your cognitive load and sharing those tasks. EPISODE RESOURCES: The Sunday Basket® The Paper Solution® The Productive Home Solution Sign Up for the Organize 365® Newsletter  Did you enjoy this episode? Please leave a rating and review in your favorite podcast app. Share this episode with a friend and be sure to tag Organize 365® when you share on social media!

Today, we will be discussing Clonidine (Catapres) and Guanfacine (Intuniv) for the treatment of ADHD.

Navigating the intricate landscape of mental health can often feel like deciphering a complex puzzle, especially when differentiating between conditions ADHD vs.anxiety. This challenge is further compounded by the similarities in symptoms and the potential for misdiagnosis. However, understanding the nuances and interconnections between these conditions can empower individuals to seek appropriate treatment and improve their quality of life. ADHD, or Attention Deficit Hyperactivity Disorder, is a neurodevelopmental condition characterized by symptoms of inattention, hyperactivity, and impulsivity. While commonly diagnosed in childhood, ADHD persists into adulthood for many individuals, affecting various aspects of their daily lives, from academic performance to personal relationships. On the other hand, anxiety disorders encompass a range of conditions marked by excessive fear, worry, and physical symptoms such as heart palpitations and dizziness. The intersection of ADHD and anxiety is a topic of significant interest within the mental health community. Individuals with ADHD often experience anxiety, partly due to the challenges and frustrations stemming from ADHD symptoms. Similarly, the constant struggle with focus and organization can exacerbate feelings of anxiety, creating a cyclical relationship between the two conditions. A critical aspect of differentiating ADHD from anxiety involves examining the onset and progression of symptoms. ADHD is present from an early age, with symptoms often becoming noticeable during childhood. In contrast, anxiety can develop at any point in life, triggered by stressors or traumatic events. Therefore, a thorough evaluation of an individual's history is vital in distinguishing between the two. Moreover, the manifestation of symptoms can offer clues. For example, while both ADHD and anxiety can lead to concentration difficulties, the underlying reasons differ. In ADHD, the inability to focus is often due to intrinsic attention regulation issues. In anxiety, however, the concentration problems may arise from excessive worry or fear that consumes cognitive resources. Understanding the unique and overlapping aspects of ADHD and anxiety is crucial for effective treatment. For ADHD, interventions typically include medication, such as stimulants, alongside behavioral strategies to enhance executive functioning skills. Anxiety disorders, meanwhile, may be treated with a combination of psychotherapy, such as cognitive-behavioral therapy (CBT), and, in some cases, medication to manage symptoms. The integration of treatment modalities is paramount, particularly for individuals experiencing both ADHD and anxiety. Addressing the ADHD symptoms can often alleviate anxiety by improving self-esteem and coping mechanisms. Similarly, managing anxiety can reduce the overall stress load, making ADHD symptoms more manageable. In conclusion, ADHD and anxiety represent two distinct yet interrelated conditions within the spectrum of mental health. The complexity of their relationship underscores the importance of personalized, comprehensive treatment plans. By fostering a deeper understanding of these conditions, individuals can navigate the path to wellness with greater clarity and confidence. This journey, though challenging, is a testament to the resilience and strength inherent in the human spirit, as we seek to understand and overcome the obstacles that lie within our minds. TRANSCRIPT Kimberley: Welcome, everybody. We are talking about ADHD vs anxiety, how to tell the difference, kind of get you in the know of what is what.  Today, we have Dr. Ryan Sultan. He is an Assistant Professor of Clinical Psychiatry at Columbia University. He knows all the things about ADHD and cannabis use, does a lot of research in this area, and I want to get the tea on all things ADHD and anxiety so that we can work it out. So many of you listening have either been misdiagnosed or totally feel like they don't really understand the difference. And so, let's talk about it. Welcome, Dr. Sultan. ADHD vs. ANXIETY  Ryan: Thank you. I really like doing these things. I think it's fun. I think psychiatrists, which is what I am, I think one of the ways that we really fail, and medical doctors in general don't do well at this, which is like, let's spend some time educating the public. And before my current position, I did epidemiology and public health. And so, I learned a lot about that, and I was like, “You know how you can help people? We have a crisis here. Let's just teach people things about how to find resources and what they can do on their own.” And so, I really enjoy these opportunities.  WHAT IS ADHD vs. WHAT IS ANXIETY?   I was thinking about your question, and I was thinking how we might want to talk about this idea of ADHD versus anxiety, which is a common thing. People come in, and they see me very commonly wanting an evaluation, and they think they have ADHD. And I understand why they think they have ADHD, but their main thing is basically reporting a concentration or focus issue, which is a not specific symptom. Just like if I'm moody today, that doesn't mean I have a mood disorder. If I'm anxious today, it doesn't mean I have an anxiety disorder. I might even feel depressed today; it doesn't mean I have a depression disorder. I could even have a psychotic symptom in your voice, and it does not mean that I have a psychotic disorder. It's more complicated than that.   I think one of the things that the DSM that we love here in the United States—but it's the best thing we have; it's like capitalism and democracy; it's like the best things that we have; we don't have better solutions yet—is that it describes these things in a way that uses plain language to try to standardize it. But it's confusing to the general public and I think it's also confusing to clinicians when you're trying to learn some of these conditions.  WHEN IS ADHD vs. ANXIETY DIAGNOSED?  And certainly, one of the things that have happened in my field that people used to talk a lot about is the idea that, is pediatric, meaning kid diagnosis of ADHD, which often in my area here in the United States will be done by pediatrician, are they adequately able to do that? Because poor pediatricians have to know a lot. And ADHD, psychiatric disorders are complicated. Mental health conditions are super complicated. They're so complicated that there are seven different types of degree programs that end up helping you with them. PsyD, PhD, MD, clinical social worker, mental health counselor, and then there's nurse practitioner. So, like super complicated counseling. So, how do we think about this?  The first thing I try to remind everyone is, if you're not sure what's going on with you, please filter your self-diagnosis. You can think about it, that's great. Write your notes down, da-da-da, but I would avoid acting purely on that. You really want to do your best to get some help from the outside. And I know that mental health treatment is not accessible to everyone. This is an enormous problem that existed before the pandemic and still exists now. I say that because I say that all the time, and I wish I had a solution for you. But if you have access to someone that you think can help you tease this throughout, you want to do that.  SYMPTOMS OF ADHD vs. ANXIETY  But what I would like us to do, instead of listing criteria, which you can all Google on WebMD, let's think about them in a larger context. So, mental health symptoms fall into these very broad categories. And so, some of them are anxiety, which OCD used to be under, but it's now in its own area. Another one, would be mood. You can have moods that are really high, moods that are really low. Another one you could take ADHD, you could lump it in neurodevelopmental, which would mix it with autism and learning disorders. You could lump it with attention, but the problem with that is it would also get lumped with dementia, which are processes that overlap, but they're occurring at different ends of the spectrum.   So, let's think about ADHD and why someone might have ADHD or why you might think someone has ADHD, because this should be easier for people to tease out, I think. ADHD is not a condition that appears in adulthood. That's like hands down. Adult ADHD is people that had ADHD and still have ADHD as adults. And most people with ADHD will go on to still have at least an attenuated version, meaning their symptoms are a little less severe, maybe, but over 60% will still meet criteria. It's not a disorder of children. Up until the ‘90s, we thought it was a disorder of kids only. So, you turned 18, and magically, you couldn't have ADHD anymore, which didn't make any sense anyway.   So, to really get a good ADHD diagnosis, you got to go backwards. If you're not currently an eight-year-old, you have to think a little bit about or talk to your family, or look at your school records. And ideally, that's what you want to do, is you want to see, is there evidence that you have, things that look like ADHD then? So, you were having trouble maintaining your attention for periods of time. Your attention was scattered in different ways. Things that are mentally challenging that require you to force yourself to do it, that particularly if you don't like them, this was really hard for you. You were disorganized. People thought that things went in one year and out the other.   Now this exists on a spectrum. And depending on the difficulty of your scholastic experience and how far you pushed yourself in school, these symptoms could show up at different times. For example, it's not uncommon for people to show up in college or in graduate school. Less so now, but historically, people were getting diagnosed as late as that, because now they have to write a dissertation. For those of you guys who don't know, a dissertation is being asked to write a book, okay? You're being asked to write a book. And what did you do? You went to college. Okay, you went to college, and then you had some master's classes, and then you get assigned an advisor, and you just get told to figure out what your project is. It is completely unstructured. It is completely self-sufficient. It is absurd. I'm talking about a real academic classic PhD. That is going to bring it. If somebody has ADHD, that's going to bring it out because of the executive functioning involved in that, the organization, the planning. I got to make an outline, I got to meet with my mentor regularly, I got to check in with them, I got to revise it, I got to plan a study or a literature review. There's so many steps involved. So, that would be something that some people doesn't come up with then.   Other kids, as an eight-year-old boy that I'm treating right now, who has a wonderful family that is super supportive, and they have created this beautiful environment for him that accommodates him so much that he has not needed any medication despite the fact that there's lots of evidence that he is struggling and now starting to feel bad about himself, and he has self-esteem issues because he just doesn't understand why he has to try so hard and why he can't maintain his attention in this scenario, which is challenging for him.   So, ADHD kids and adults, you want to think of them as their brains as being three to five years behind everyone else in their development, okay? And they are catching up, but they're more immature, and they're immature in certain ways. And so, this kid's ability to maintain his attention, manage his own behaviors, stay organized, it's like mom is sitting with this kid doing his homework with him continuously, and if she stops at all, he can't hold it together on his own. So, when we think about that with him, like, okay, well, that's maybe when it's showing up with him. That's when it's starting to have a struggle with him.   But let's relate it to anxiety. One problem would be, do you have ADHD or do you have anxiety? Well, there's another problem. Another problem is having ADHD is a major risk factor for developing an anxiety disorder, okay? So now I'm the eight-year-old boy, and this eight-year-old boy does not have the financial resources to get this evaluation, or the parents that are knowledgeable enough to know that, it might even have been years ago where there was less knowledge about this. And he's just struggling all the time, and he feels bad about himself, and he's constantly getting into trouble because he is losing things because he can't keep track of things because he's overwhelmed. And now he feels bad about himself. Okay. He has anxiety associated with that. So now we're building this anxiety. So he might even get mood symptoms, and now we have a risk for depression.   So, this is just one of the reasons why these things are like these tangled messes. You ever like have a bunch of cords that you have one of the dealies, you keep throwing them in a box, and now you're like, “What do I do? Do I just throw the cords out or entangle them?” It's a very tangled mess. Of course, it takes time to sort through it. The reason I started with ADHD is that it has a clear trajectory of it when it happens. And in general, it's a general rule, symptomatology, meaning like how severe it is and the number of symptoms you have and how impairing it is. They're going to be decreasing as you get older. At least until main adulthood, there's new evidence that shows there might be a higher risk for dementia in that population.   But let's put geriatric aside. There's a different developmental trajectory. Whereas anxiety, oh God, I wish I could simplify anxiety that much. Anxiety can happen in different ways. So, let's start with the easy thing. Why would you confuse them in this current moment? If I am always worried about things, if I'm always ruminating about things, I'm thinking about it over and over again, I'm trying to figure out where I should live or what I should do about this, and I just keep thinking about it over and over again, and I'm in like a cycle. Like, pop-pa-pa pop-pa pop-pa-pa-pa. And then you're asking me to do other things. I promise you, I will have difficulty concentrating. I promise you, I can't concentrate because it's like you're using your computer and how many windows do you have open? How many things are you running? I mean, it doesn't happen as much anymore, but I think most of us, I meant to remember times where you're like, “Oh, my computer is not able to handle this anymore.” You're using up some of your mind, and you can call that being present.   So, when people talk about mindfulness and improving attention, one of the things that they're probably improving is this: they're trying to get the person to stop running that 15, 20% program all the time. And it's like your brain got upgraded because you can now devote yourself to the task in front of you. And the anxiety is not slowing you down or intruding upon you, either as an intrusive thought in an OCD way or just a sort of intrusive worry that's probably hampering your ability to do something concentration-intensive. And then if you have anxiety problems and you're not sleeping right, well, now your memory is impaired because of that. So, there's this cycle that ends up happening over and over again.  IS HYPERACTIVITY ANXIETY OR ADHD? Kimberley: Yeah, I think a lot of people as well that I've talked to clients and listeners, also with anxiety, there's this general physiological irritability. Like a little jitteriness, can't sit in their chair, which I think is another maybe way that misdiagnosis can -- it's like, “Oh, they're hyperactive. They're struggling to sit in their chair. That might be what's going on for them.” Is that similar to what you're saying?  Ryan: Yeah. So, really good example, and this one we can do a little simpler. I mean, the statement I'm going to say is not 100% true, but it's mostly true. If you are an adult, like over 25 for sure, and you are physically jittery, it is very unlikely that that is ADHD. Because ADHD, the whole mechanism as we understand it, or one of the mechanisms causing the thing we call ADHD, which of course is like a made-up thing that we're using to classify it, is that your prefrontal cortex is not done developing. So, it needs to get myelinated, which is essentially like -- think about it like upgrading from dial up to some great, not even a cable modem. You're going right to Verizon Fios. Like amazing, okay. It's much faster, and it's growing. And that's the part of you that makes you most human. That's the most sophisticated part of your brain. It's not the part that helps you breathe or some sort of physiological thing, which, by the way, is causing some of those anxiety symptoms. They're ramped up in a sympathetic nervous system way, fight or fight way. It's the part that's actually slowing you down. That's like, “Whoa, whoa, whoa, whoa, whoa, calm down, calm down, calm down.” This is why, and everyone's is not as developed. So, we're all developing this thing through 25, at least ADHD is through 28.   Car insurance goes down to 25 because your driving gets better, because your judgment gets better, because you can plan better, because you are less risk-taking. So, your insurance has now gone down. So, the insurance company knows this about us. And our FMRI scans, you scan people's brains, it supports that change. These correlate to some extent with symptomology, not enough to be a diagnosis to answer the person's question that they're going to have that. I wish it was. It's not a diagnosis. We haven't been able to figure out how to do that yet.   So, by the time you're 25, that's developed. And the symptoms that go away first with ADHD are usually hyperactivity, because that's the inability to manage all the impulses of your body, not in an anxious, stressed-out way, but in an excited way. You think of the happy, well-supported, running around ADHD kid is kind of silly and fun. It's a totally different mood experience than the anxiety experience. Anxiety experience is unpleasant for the most part. Unless your anxiety is targeting you to hyper-focus to get something done, which is bumping up some of your dopamine, which is again the opposite experience of probably having ADHD, it's a hyper-focus experience, certainly, the deficit part of ADHD, you're going to be feeling a different physiological, the irritability you talked about 100%. You're irritable because you are trying so hard to manage this awful feeling you have in your body. You physically feel so uncomfortable. It is intolerable.   I have this poor, anxious young man that has to do a very socially awkward thing today. Actually, not that socially awkward. He created the situation, which is one of the ways we're working on it with him in treatment. And I'm letting him go through and do this as an exposure because it'll be fine. And he's literally interacting with another one of our staff members. But he finds these things intolerable. He talks about it like we are lighting him on fire. So, he's trying to hold it together, or whatever your physiological experience is. It may not have been as dramatic as I described. You're irritable when people are asking things of you because you don't have much left. You're not in some carefree mood where you're like, “Whatever, I'm super easygoing. I don't care.” No, you're not feeling easygoing right now. You're very, very stressed out.   Stress and anxiety are very linked. Just like sadness and depression are very linked, and like loneliness and depression are linked, but they're not the same thing. Stress and anxiety are very, very linked, and they're similar feelings, and they're often occurring at the same time and interacting with each other. ADD vs. ADHD  Kimberley: Right. One question really quick. Just to be clear, what about ADD vs. ADHD?  Ryan: We love to change diagnostic criteria. People sit around. There's a committee, there's a whole bunch of studies. And we're always trying to epidemiologically and characterologically differentiate what these different conditions are. That's what the field is trying to do as an academic whole. And so, there's disagreements about what should be where. So, the OCD thing moving is one of them.   The ADD thing, it's like a nomenclature thing. So, the diagnosis got described that the new current version of the diagnosis is attention deficit hyperactivity disorder, and then you have three specifiers, okay? So, that's the condition you have. And then you can have combined, which is hyperactive and inattentive. Just inattentive, just hyperactive. And impulsive is built in there. So, it's really not that interesting. People love to be like, “No, no, I have ADD. No, I don't have the hyperactive.” And I'm like, “I know, but from a billing point of view, the insurance company will not accept that code anymore. It doesn't exist.” DOES ADHD OR ANXIETY IMPACT CONCENTRATION?  Kimberley: Yeah. So, just so that I know I have this right, and you can please correct me, is if you have this more neurological, like you said, condition of ADHD, you'll have that first, and then you'll get maybe some anxiety and some depression as a result of that condition. Whereas for those folks, if their primary was anxiety, it wouldn't be so much that anxiety would cause the ADHD. It would be more the symptoms of concentration are a symptom of the anxiety. Is that what you're saying? Ryan: Yes, and every permutation that you can imagine based on what you just said is also an option. Like almost every permutation. Like how are they interacting with each other? How are they making each other worse? How are they confusing each other? Because you can have anxiety disorders in elementary school. I mean, that is when most anxiety disorders, the first win, like the wave of them going up is then. And you think about all the anxiety you have.   I got a friend of mine who's got infants. And it's fun to see like as they're developing, when they go through normal anxiety, that that is a thing that they're going to pass. And then there's other things where, at some point, we're like, actually, now we're saying this is developmentally inappropriate, which means, nope, we were supposed to have graduated from this and it's still around.   And so, one of the earlier ways that psychiatric conditions were conceptualized, and it's still a useful way to conceptualize them, is the normal behavior version of it versus the non-normal behavior version of it. And again, I hate non-normal, I don't want to pathologize people, but non-normal being like, this is causing problems for you. And if you think about it from an evolutionary point of view, all of these conditions have pretty clear evolutionary bases of how they would be beneficial. Anxiety is going to save your ass, okay? Properly applied anxiety, it'll save your tribe. You want someone who's anxious, who's going to be like, “We do not have enough from this winter.” An ADHD person was like, “It'll be fine. I'm just going to go find something else.” And you're like, “No.” And then when that winter's really bad and you save that little bit of extra food, that 30% that the anxious person pushed for, maybe you didn't eat all 30% of it, but you know what, it probably benefited you and it might've actually made the whole tribe survive or more people survive or better health condition. So, it's approving everyone's outcomes.   The ADHD individual, you get them excited about something—gone. They're going to destroy it. They're going to find all the berries. They're going to find all the new places. They're going to find all the new deer. They're going to run around and explore. It's great. Great, great, great.   Depression is like hibernation. And if you look at hibernation in a mammal, like what happens, there's a lot of overlaps. Lower energy, maybe you store up some food for the winter. It's related to the seasons. You're in California, right? This is not a problem you have, but for those of us in New York, where we have seasonality, seasonal depression is a thing. It's very much a thing. It's very noticeable, and it's packed on top of these conditions everyone else is having.  But the idea is that the hibernation or the pullback is like something happens to you that upsets you, which is the psychosocial event that's kicking you in the face that might set off your depression. That's why people always say, “Oh, depressions just don't come out of nowhere. This biochemical thing isn't true.” What they're saying is something has to happen to start to kick off the depression, but that's not enough. It's that you then can't recover from it.   And so, a normal version of it is that you get knocked out and you spend a week or two, you think about it. Rumination is a part of depression for many people. You reevaluate, and you say, “You know, I got kicked in the face when I did that. That was not a good plan for me. I need a new plan. I either need to do something different or I need to tackle that problem differently.” And so, that would be the adaptive version of a depressive experience. Whereas the non-adaptive version is like, you get stuck in that and you can't get out.  Kimberley: Or you avoid.  Ryan: The avoiding doing anything about it, and then that makes it worse. So, you started withdrawing. I mean, that's the worst thing you can do. This is a message to everyone out there. The worst thing that you can do is withdraw from society for any period of time. Look, I'm not saying you can't have a mental health day, but systematic withdrawal, which most of us don't even realize is happening, is going to make you worse because the best treatment for every mental health condition is community. It is really. All of them. All of them, including schizophrenia.   I used to work in Atlanta. I did my residency. There'd be these poor guys that have a psychotic disorder. They hear voices. The kinds of people that, here in New York City, are homeless, they're not homeless there. Everyone just knows that Johnny's just a little weird and his mom lives down the street. And if we find Johnny just in the trash can or doing something strange, or just roving, we know he's fine, and someone just takes him back to his mom's house and checks on him. Because there's a community that takes care of him, even though he's actually quite ill from our point of view. But when you put him in an environment where that community is not as strong, like a city, it does worse, which is why mental health conditions are much higher rates in urban areas. Probably why psychiatry and mental health in general is such a central thing in New York City. TREATMENT FOR ADHD vs. ANXIETY  Kimberley: Yeah. Okay, let's talk quickly about treatment for ADHD. We're here always talking about the treatment for anxiety, but what would the research and what's evidence-based for ADHD if someone were to get that clinical diagnosis?  Ryan: So, you want to think about ADHD as a thing that we're going to try to frame for that person as much as how is it an asset, because it historically has made people feel bad about themselves. And so, there are positive aspects to it, like the hyper focus and excitability, and interest in things. And so, trying to channel into that and then thinking about what their deficits are. So, they're functional deficits. If you're talking adult population, functional deficits are going to be usually around executive functioning and organization planning. Imagine if you're like a parent of small children and you have untreated ADHD, you're going to be in crazy fight-or-flight mode all the time because there's so many things to keep track of. You have to keep track of your wife and their life. Kimberley: I see these moms. My heart goes out to them. Ryan: And they're probably anxious. And the anxiety is probably protecting them a little bit. Because what is the anxiety doing? You think about things over and over and over again, and you double check them. You know what that's not a bad idea for? Someone who's not detail-oriented, who's an ADHD person, who forgets things, and he gets disorganized. So, there's this thing where you're like, “Okay, there may actually be a balance going on. Can we make the balance a little bit better?” So, how do you organize yourself?  MEDICATIONS FOR ADHD Right now, there's a stimulant shortage. Stimulants are the most effective medication for reducing ADHD symptoms. They are the most effective biological intervention we have to reduce the impact of probably any psychiatric condition, period. They are incredibly effective, like 80, 90% resolution of symptoms, which is great. I mean, that's great. That's great news. But you also want to be integrating some lifestyle changes and skills alongside of that. So, how do you organize yourself better? I mean, that's like a whole talk, but like lists, prioritizing lists, taking tasks, breaking them down into smaller and smaller pieces. Where do you start? What's the first step? Chipping away. You know what? If you only go one mile a day for 30 days, you go 30 miles. That's still really far. I know you would have gone 30 miles that day, especially if you have ADHD, but you're still getting somewhere.  And so, that kind of prioritization is really, really important. And so, you can create that on your own. There are CBT-based resources and things to try to help with that. There are ADHD coaches that try to help with that. It's consistency and commitment around that. So, how do you structure your life for yourself? That poor PhD candidate really needs to structure their life because there is no structure to their life.  The other things we want to think about with that, I mean, really good sleep, physical exercise. People with ADHD, we see on FMRI scans when you scan someone's brain, there's less density of dopamine receptors, less dopamine activity. You want to get that dopamine up. That's what the medications are doing, is predominantly raising the dopamine. So, physical activity, aerobic exercise, in particular, is going to do that. Get that in every day, and look, it's good for you. It's good for you. There is no better treatment for every condition in the world other than exercise, particularly aerobic. It basically is good for everything. If you just had surgery, we still want you to get out and walk around. Really quickly, that actually improves your outcome as fast as possible. So, those are the things I like people to start with if they can do that, depending on the severity of what's going on, the impact, what other things have already been tried. Stimulant medications or non-stimulant medications like Wellbutrin, Strattera, Clonidine are also pretty effective. Methylphenidate products, which is what Ritalin is. Adderall products mixed in amphetamine salts, Vyvanse, these are very effective medications for it. There's a massive shortage of these medications that people are constantly talking about, and is really problematic and does not appear to have an endpoint because the DEA doesn't seem ready to raise the amount that they allow to be made because they are still recovering from the opioid crisis, which is ongoing. And so, they're worried about that. Really, they want to be very thoughtful about this. These medications have a very low-risk potential for misuse. In fact, people with ADHD, they appear to reduce the risk of developing a substance use disorder. It's the most common thing that people worry about. So, treatment actually reduces that.  That said, the worst -- I mean, I don't want to say the worst thing. I mean, people hate me. The really not great way to get psychiatric treatment is to show up to someone once and then intermittently meet with them where they write a prescription for a medication for you that's supposed to help you, and stimulant medications are included on that. So, that's probably why I didn't lead with that, even though there's actually more science to support them, is that by themselves, it's really going to limit how much help you're going to get. Kimberley: Can you share why? Ryan: Because you need to understand your condition, because you need to spend time with your clinician learning about your condition and understanding how it's affecting your life, and understanding how the medication is actually meant to be a tool. It should be like wearing glasses. It doesn't do the work for you. It doesn't solve all your problems, but it's easier to read when you put your glasses on than without it. It supports you. You still need to figure out how to get these things done. It lowers the activation energy associated with it. But you also want to monitor it. You can't take these medications 24 hours a day and just be ready to go and work, which is things that people have tried. It doesn't work because you need to sleep, because you will die. They've tried this. We know that you will literally die, like not sleeping. And in the interim, you are damaging yourself significantly. So, taking it and timing it in an appropriate way, still getting sufficient sleep, prioritizing other things—they are like a piece of a puzzle, and they are a really powerful piece. But you really don't want that to be the only thing driving your decision-making, or that be what the interaction is really about. And by the way, the same thing is true for all psychiatric medications. Kimberley: I was going to say that's what we know about OCD and anxiety disorders too. Medication alone is not going to cut you across the line.  Ryan: And for most people, therapy alone is also not going to cut the line. You have to have a mild case for therapy alone to be okay. And I can trouble for that statement. But the other thing is lifestyle. What lifestyle changes can I make? And those together, all three, are going to mean that you get better faster, you get more better than you would have, you're more likely to stay better. And they start to interact with each other in a good way, where you get this synergistic effect of ripples of good things happening to you and personal growth. You look back, and you're like, “Geez, I'm on version 3.0 of me. I didn't know that there was a new, refined personal growth version of me that could actually function much better. I didn't actually believe that.” DOES ADHD IMPACT SELF-ESTEEM?  Kimberley: Well, especially you talked about this impact to self-esteem too. So, if you're getting the correct treatment and now you're improving, as you go, you're like, “Okay, I'm actually smart,” or “I'm actually competent,” or “I'm actually creative. I had no idea.”   Ryan: Yes. “I'm not stupid.” Lots of people with ADHD think they're stupid.   Kimberley: Yeah. So, that's really cool. One question I have that's just in my mind is, does --  Ryan: And that should be part of your treatment, is the working through. That was essentially a complex trauma. It's the complex trauma of having this condition that may not have been treated that made you think that you were an idiot because you were being shoved into a situation that you did not know how to deal with because your ADHD evolved to be an advantage for you as a hunter-gatherer for the hundreds of thousands of years that we had that, and that modern world is not very compliant for. It doesn't experience you as fitting into it well. And then you feel bad about yourself. ADHD IN MALES vs. FEMALES  Kimberley: Right. You're the class clown, or you're the class fool, or the dumb girl, or whatever. Now, my last question, just for my sake of curiosity, is: does ADHD look different between genders?  Ryan: This is an area of significant research. So, historically, the party line has been that ADHD is significantly more common in boys and girls. And the epidemiology, the numbers, the prevalence have always supported that. Like 3 to 1, 2 to 1, like a much more, much more common. Refining of that idea has come up with a couple of thoughts. One, for whatever reason, I don't know how much of this is genetic. I have no idea how much of this is environmental, sociological. All other things being equal, after a certain young age, girls just always seem to be ahead of boys in their development. I mean, talk to any parent that's had a lot of kids, and they'll tell you that they're like, “I don't know why the girls are always maturing faster.” So, that's a bias that is going to always make at any given point. The boys look worse because their brains are not developed. So, they're going to be -- remember that immature younger thing? They're going to be immature and younger. And so at any given marker is that.  The other thing that's come up is that the hyperactivity seems to be something we see a lot more in males than in females. That's another thing. And versus inattentiveness, which you see in both and is usually the predominant symptom. And the kid who gets noticed is the little boy who's like -- I mean, not that you could do this in today's world, but has scissors and is about to cut a kid's cord. I'm trying to make a silly imagery. That kid's getting a phone call. No one didn't notice that. The whole class called that. Whereas like daydreaming, I'm not really listening—this is a more passive experience of ADHD. And they're not disrupting the room. Forget about the gender thing. Just that presentation is also less noticed.   So, I think the answer is the symptomology presentation is a little different. It tends to be predominantly hyperactive. Are the rates different? Yes, they're probably not as wide of a difference as we think they are, because we're probably missing a good number of girls. Are we missing enough girls to make it 50/50? I don't know. That would be a lot of -- it's a big gap. It's not close. It's a pretty big gap. Maybe we're certainly missing some.   And then the other aspect of it is particularly post-puberty. Even before puberty, there's hormonal changes going on. And these hormones, particularly testosterone, which is present in everyone, we think about it as a male thing, but it's really just like a balance thing. You have significant amounts of both. It affects a number of things, and attention is one of them. So, there's so many complexing factors to it. That's why I said, it's something we're still trying to sort out.   One of the things that's really interesting that goes back to the hormone thing is that if you talk to young women— so postmenstrual, they've gone through puberty—they will tell you over and over again that their symptomology, just like we have mood symptoms tend to be worse during that time period of when you're ovulating, the ADHD symptoms will be worse as well. And so, there's increasing evidence that if you're on ADHD medication and you have ADHD, which again, we're making lots of presumptions here, go get that confirmed, guys. But if you're on that time period just leading up to ovulation a little bit after, you may actually need a higher dose of your medication to get the same effect. That there's something about the way progesterone and whatever is changing that it affects functionally your attention and your experience of your symptomatology.   Kimberley: Interesting. Yeah, thank you for sharing that. Is there anything you feel like we've missed or a point you really want to make for the folks who are listening who are trying to really untangle, like you said, that imagery of untangle, anxiety, ADHD, all of the depression, self-esteem?  Ryan: This is like a sidebar that's related. So, one of my other areas of interest is cannabis. And here in New York, we've had a lot going on with cannabis. And there's a lot of science going on around, can cannabis be used to treat things, particularly psychiatric disorders? And I know that a lot of people are interested in that.  One of the things that I've been really trying to caution people around with it is that the original thing that I was probably taught in the ‘90s about cannabis, marijuana being like this incredibly unsafe thing, is not true. But the narrative that it's totally fine and benign is also not true. And that it is probably going to be effective in reducing anxiety acutely, and it will probably be effective in maybe even improving your mood. And some people with ADHD even think it improves their attention by calming their mind. I am very cautious about people starting to use that as part of their treatment plan. And I can tell you why.  Kimberley: Because you did say there's an increase in substance use.  Ryan: The problem is that it's not rolled out in a way that reflects an appropriate medical treatment. So, if you do it recreationally, obviously, it's basically like alcohol. You just get what you want, and you decide what you want. If you do it medically, depending on the state, as a general rule, you just get a medical card and then you decide what you're going to do, which just seems crazy to me. I mean, you don't do that. You don't send people home with an unlimited amount of something that is mind-altering and tell them to use as much as they need. And the potencies, the strength of it has gotten stronger and stronger.   And so, I really caution people around this because when you use it regularly, what ends up happening is you get this downregulation, particularly daily use. You get this downregulation of your receptors, your cannabinoid receptors. We all have cannabinoid receptors. And you have fewer and fewer of them. And because you have so much cannabinoid in your system because you're getting high that your body says, “I don't need these receptors.” So then when you don't get high, those cannabinoid receptors that modulate serotonin, dopamine—so functionally, your attention, your mood, your anxiety level—there's none of them left because they've been getting bound like crazy to this super strong thing. And you're making almost none yourself, so you're going to feel awful. You're going to feel awful. And it's not dosed in any kind of appropriate way. We're not giving people guidance on this.   So, I really caution people when they're utilizing this, which the reality is that a lot of people are, that they be thoughtful about that and thoughtful about the frequency that they're using and the amounts that they're using, and if they're at a point where they're really trying to self-medicate themselves, because that can really get out of control for people. They can get really out of control. And I think it's unfortunate that we don't have a better system to help people with that. That is more like the evaluation of an FDA-approved medication or something like that has a system through it.   So, I just wanted to add that because I know this is something that a lot of people are thinking about. And I think it can be hard to get really good science information on since there's a big movement around making this change. When we're doing a big movement around pushing for a change, we don't want to talk about the reasons that the change might be a little problematic, and therefore slow the change down. So, we forget about that. And I think for the general public, it's important to remember that.  Kimberley: Yeah, I'm so grateful that you did bring that up. Thank you. Where can our listeners learn more about you or be in touch with you?  Ryan: So, if they want to learn more about my practice, my clinical practice, integrativepsych -- no, integrative-psych.org. We changed. We wrote .nyc. There we go. And then if you want to learn about my science and my lab and our research, which we also love, if you just go to Sultan (my last name) lab.org, it redirects to my Columbia page, and then you can see all about that and send some positive vibes to my poor research assistants that work so hard.   Kimberley: Wonderful. I'm so grateful for you to be here. Really, I am. And just so happy that you're here. So much more knowledgeable about something that I am not. And so, I'm so grateful that you're here to bring some clarity to this conversation, and hopefully for people to really now go and get a correct assessment to define what's going on for them.  Ryan: Yeah, I hope everyone is able to digest all this. I said a lot. And can hopefully make better decisions for themselves for that. Thank you so much.  Kimberley: Thank you.

Dr. Ferghal Armstrong and Dr. Manu Bhatnagar delve into the complexities of non-stimulant treatments for ADHD and the pharmacological aspects involved. In this episode, the experts discuss the roles of clonidine, guanfacine, and melatonin in managing ADHD symptoms, particularly focusing on improving sleep quality and addressing underlying neurobiological factors. Their insights into the impact of lifestyle, substances, and the circadian rhythm on ADHD provide valuable information for both individuals managing the condition and healthcare professionals seeking effective treatment strategies.Focus Keyword: ADHD non-stimulant treatmentsKey Points:- The episode discusses the pharmacological aspects of non-stimulant treatment options for ADHD.- The roles of clonidine, guanfazine, and melatonin in managing ADHD symptoms, particularly sleep disturbances, are explored in detail.- The impact of substances, lifestyle factors, and the circadian rhythm on ADHD symptoms is highlighted.- The implications of ADHD on sleep architecture and strategies for managing this aspect are deeply delved into.Learning Outcomes:1. Understanding the Role of Clonidine and Guanfacine:Clonidine, initially developed for lowering blood pressure, has shown effectiveness in managing ADHD symptoms, particularly in enhancing sleep quality. Guanfacine, although not widely used due to cost and regulatory concerns, presents a promising alternative with a longer duration of action. By understanding the mechanisms and impacts of these medications, healthcare providers can make informed decisions regarding non-stimulant ADHD treatments, considering factors such as duration of action and potential adjunctive benefits.2. Addressing Sleep Disturbances in ADHD:The episode sheds light on the correlation between ADHD and delayed sleep phase disorder, underscoring the significance of sleep in managing ADHD symptoms. Insight into the application of melatonin, lifestyle interventions, and lightbox therapy as components of a comprehensive sleep management strategy can equip individuals and healthcare professionals with valuable tools for improving sleep quality in individuals with ADHD.Actionable Takeaways:1. Optimizing Non-Stimulant ADHD Treatments:Utilize the knowledge of clonidine and guanfacine as effective non-stimulant treatments for ADHD, considering factors such as the patient's response, duration of action, and adjunctive benefits in tailoring treatment plans.2. Implementing Comprehensive Sleep Management Strategies:Incorporate strategies such as melatonin supplementation, lifestyle modifications including exposure to morning light, and sleep hygiene practices to address sleep disturbances in individuals with ADHD, fostering better overall symptom management.Quote:"Abstinence in and of itself can be one treatment for ADHD." - Manu Bhatnagar

It's time for some Advanced Q+A with Dr. Jeffrey Strawn about medication treatment for ADHD +/- Anxiety!?Q:? When do you use alpha agonists (like Clonidine, Guanfacine)??A:  as adjunctive treatment for kids who are having trouble tolerating stimulants,  and/or who have residual impulsivity when they're being treated with stimulants.  Q: How can you prescribe alpha-agonists to kids who cannot swallow pills?A: We've talked about the possibility of using compounding pharmacies to help create liquid formulations of certain short acting alpha agonists for kids who have trouble swallowing pills. Q: When/ would you *start* treatment for ADHD with an alpha-agonist?A: Almost Never.  Start with stimulant medication when you're considering medication treatment for ADHD, regardless of how old the child is.   So for preschool aged children with ADHD for whom you're considering medication treatment, start with stimulant medication as opposed to non-stimulant medication.  Side note: Atomoxetine or Straterra is not as effective as first-line treatments for ADHD, nor is it as effective as our first-line treatments for anxiety. And finally we covered the amazing resource of Case Studies: Stahl's Essential Psychopharmacology: Volume 4: Children and Adolescents by Jeffrey R. Strawn and Stephen M. Stahl | Nov 9, 2023 available on Amazon and through Cambridge University PressCheck out our website PsychEd4Peds.com for more resources.Follow us on Instagram @psyched4peds

Is there a go-to medication to treat a child with both ADHD and anxiety?  Join us as we continue the conversation with Dr. Jeffrey Strawn from Cincinnati Children's Medical Center to discuss how to approach medication treatment for a child with ADHD and anxiety.  We talk about which stimulants are better tolerated, when to use alpha 2 agonists (like clonidine and guanfacine), and finally what to know about the norepinephrine reuptake inhibitors, Viloxazine (Qelbree) and atomoxetine (Strattera). Key Points:1 – treat ADHD first, then address residual anxiety (unless anxiety is Severe)2 – When treating ADHD, start with stimulants;  Methylphenidate (MPH) stimulants are less likely to cause mood/anxiety sxs than mixed-amphetamine salts; MPH stimulants also have  ½ incidence of appetite suppression relative to the mixed-amphetamine salts3 – When to use alpha 2-agonistso   Clonidine is “a little messier” – hits multiple receptors (alpha 2a, 2b, 2c; hits imidazoline receptor), more likely to affect BP, sedation; best for problems initiating sleep o   Guanfacine – “much more selective for alpha 2 A receptor”,o   Guanfacine XR can be dosed once daily (vs. clonidine xr which is still BID) o   Dosing and titration of Guanfacine XR stay below 6mg, 0.1 mg/kg/dayo   Guanfacine XR considered as adjunctive med in addition to SSRI for anxietyo   Good to help w/ impulsivity4 – Viloxazine/Qelbree (NRI) “what's hype vs. what's clinically relevant pharmacology?”o   Works more rapidly than atomoxetine: Even within first couple of weeks, noticing improvement in symptomso   Little 2D6 metabolism, but not affected by 2D6 metabolizer status like atomoxetine (did you know fda recommends different dosing/titration based on metabolizer status in atomoxetine)o   Potent CYP 1A2 inhibitor (which metabolizes caffeine/energy drinks)  increase caffeine exposure (blood level over time) six fold ** ADR2A genetic polymorphism means 2/3 people do NOT experience anxiety when they consume caffeineDr. Jeff Strawn is a Professor of Psychiatry and Behavioral Neuroscience at the University of Cincinnati College of Medicine.  Dr. Strawn directs the Anxiety Disorders Research Program and conducts clinical trials and neuroimaging studies in patients with anxiety and related disorders.  He is an internationally recognized expert int he field of child and adolescent anxiety disorders.Check out our website PsychEd4Peds.com for more resources.Follow us on Instagram @psyched4peds

Hello friends! In today's episode, we delve into two compelling listener questions that I'm sure many of you will find relatable and insightful. Navigating Therapy with a Talkative Therapist: One listener shares their experience with a therapist who often overshadows the session with personal stories, leaving them feeling unheard. This is particularly challenging as the listener is dealing with a controlling spouse with dementia. We explore the importance of feeling heard in therapy, the role of therapist's self-disclosure, and the value of assertiveness in therapeutic relationships. We also discuss the concept of transference and how it can impact therapy sessions. Considering Alternatives to Adderall: Another listener seeks advice about a close relative looking to taper off Adderall, which they've been dependent on for managing ADHD. We discuss the complexities of ADHD diagnosis and treatment, delve into the pharmacology of Adderall, and explore its side effects and potential for psychological dependence. Additionally, we examine Provigil (Modafinil) as an alternative, highlighting the differences in abuse potential and side effects. We also touch upon other medication options like Strattera, Intunive, Clonidine, and Wellbutrin, and emphasize the role of therapy and coaching in managing ADHD. As always, your questions and stories bring a depth of understanding to our discussions. If there's something on your mind, don't hesitate to reach out at duffthepsych@gmail.com. For full show notes, please visit http://duffthepsych.com/episode375. --- This episode is brought to you by Babbel, the science-backed language-learning app with quick, 10-minute lessons tailored to your level. Get 55% off your subscription at babbel.com/duff and start speaking a new language in as little as three weeks. Rules and restrictions may apply. This episode is also sponsored by BetterHelp, the convenient online therapy service. Reflect on your strengths and build on them with a licensed therapist, tailored to your needs and schedule. Visit betterhelp.com/duff to get 10% off your first month and start celebrating your progress.

Drs. Hope Rugo and Kristin Rojas discuss advances in the management of menopausal symptoms, fertility preservation, and bone health for women on endocrine therapy for breast cancer. TRANSCRIPT Dr. Hope Rugo: Hello. I'm Dr. Hope Rugo, your guest host of the ASCO Daily News Podcast today. I'm a professor of medicine and director of breast oncology and clinical trials education at the University of California San Francisco's Comprehensive Cancer Center. And I'm also an associate editor of the ASCO Educational Book.   In patients with hormone receptor positive breast cancer, the most common subset of the most common cancer in women worldwide, adjuvant endocrine therapy significantly reduces the risk of recurrence and death. However, prolonged estrogen suppression associated with the use of endocrine therapy can cause life-altering menopausal symptoms, bone loss, and fertility concerns. These issues impact the use of endocrine therapy and potentially breast cancer outcome.    Today, we'll be discussing mitigation strategies to manage the side effects of endocrine therapy, which we hope will improve our patient's quality of life and adherence to treatment with Dr. Kristin Rojas, who addressed these issues in a recently published article in the 2023 ASCO Educational Book. Dr. Rojas is an assistant professor of surgery and a breast surgical oncologist and gynecologic surgeon at the University of Miami Sylvester Comprehensive Cancer Center.    Our full disclosures are available in the transcript of this episode, and disclosures of all guests on the podcast can be found in our transcripts at asco.org/DNpod.    Dr. Rojas, thank you for being on the podcast today.   Dr. Kristin Rojas: Thanks, Dr. Rugo, thank you so much for having me. Thank you to ASCO as well. It's truly an honor to be here with you today.  Dr. Hope Rugo: Your excellent article provides an updated overview of the existing approaches and a little forward thinking for improving the quality of life of breast cancer patients who are receiving estrogen deprivation therapy, a really broad term we use for all the hormone therapy we use in ovarian function suppression in the treatment of breast cancer. And then you had a very nice session education session at the ASCO Annual Meeting discussing these issues. Can you briefly discuss the educational session, your speakers and topics, and then we'll get more into the details of this important topic?   Dr. Kristin Rojas: At our educational session at ASCO this year, I chaired the session and presented on managing the sexual side effects and menopausal symptoms of estrogen suppression. And I had two wonderful colleagues with me: Dr. Matteo Lambertini, who shared guidelines regarding bone-targeted agents and managing bone health during endocrine suppression. And then we also had Dr. Terri Woodard, who is a reproductive endocrinologist from MD Anderson, who spoke on managing fertility concerns, which is a very important topic right now.   Dr. Hope Rugo: Yeah, that's great. And it was such a fabulous session. Our listeners can view it online at asco.org if you missed this session. But let's talk a little bit about what was in your article and what was discussed. First, I think the physical and psychological effects of cancer care we know are critical components of survivorship care. Can you tell me a little bit more about that and how we need to understand that as oncologists?  Dr. Kristin Rojas: So, as you know, as treatment continues to improve, our cancer outcomes are improving and the population of survivors continues to grow. So, I think that for many breast cancer patients, or having the diagnosis of breast cancer, becomes more of a chronic illness and less a life-threatening issue for some. I think that the conversation is now changing from “Will you live?” to “How will you live?” And I was thrilled to see that other big organizations, along with ASCO, are prioritizing managing these important symptoms in survivorship. Because I think that, as most patients will be on some form of estrogen suppression, managing the toxicity of these therapies, as you pointed out, probably does influence treatment adherence, which directly translates to an oncologic improvement. So, it's not just managing these soft symptoms, it actually will have a direct influence on probably overall survival along with disease-free survival.  Dr. Hope Rugo: Yeah, I think that's incredibly important and it's not just about doing the exam and finding out symptoms that might signify recurrence, it's really trying to address the effects of the treatment patients have gotten of chemo and their ongoing treatment with endocrine therapy that's so incredibly important. And now, of course, in medical oncology, we're adding on more agents which add to symptoms. That'll be the topic of next year's ASCO educational session. What do you do with the CDK4/6 inhibitors and managing those. But in more than 80% of women who are on the antiestrogen or various, I'm going to call hormone therapies, for early-stage breast cancer, vasomotor symptoms are a big issue. They're typically more severe in younger patients because of course they have estrogen and we take it away. So, how do we mitigate this problem in patients that can result in poor sleep and impact many aspects of one's psychosocial status? And these issues, not sleeping, of course, you make everything worse.  Dr. Kristin Rojas: Yeah, that's a really important point. And you're right, this is a really common symptom experienced by the majority of patients on endocrine suppression. And not only those patients, but patients with triple negative disease who are put into menopause from chemotherapy, etc., along with women with cancer of other disease sites. And so, as the director of our program at the Sylvester Comprehensive Cancer Center, the program is called MUSIC, which stands for Menopause Urogenital Sexual Health and Intimacy Clinic.    This is a very common symptom that patients often report. And one of the important things about this that I've realized is that hot flashes or vasomotor symptoms can actually have a pretty varied presentation. So, it's not just intense sweating. Sometimes these patients can present with palpitations, panic attacks, and they don't even realize that they're hot flashes. This is an effect of estrogen suppression and it's a central mechanism. So, it's probably related to hypothalamic dysregulation regarding how our body senses temperature changes, but it results in widespread flushing and sweating and those other aspects I told you about.   So, we've known for a long time that there are some behavioral modifications that can help with vasomotor symptoms or hot flashes. But now, we actually do have some pretty effective pharmacologic therapies for these patients as well, for whom behavioral modifications aren't completely helping the issue. Or, as you said, when patients are being woken up all night long with these hot flashes, it totally disrupts how their day goes and disrupts coping with their disease and all the other aspects of their treatment.   So, there's some effective treatments that we have. One of those being cognitive behavioral therapy has been shown to be helpful. The data on acupuncture is mixed, but I'm hopeful about this. And then the pharmacologic therapies we have. Traditionally or historically, clonidine, which is an alpha agonist, has been used along with gabapentin. But I think when choosing a medication to prescribe to a patient for hot flashes, you have to take into account the side effect profile. Clonidine does have some issues with blood pressure rebound, and gabapentin is really only effective in large doses, which can be very sedating for patients.    In the MUSIC Sexual Health After Cancer program, we typically stick to low dose SSRIs or SNRIs. I usually go with venlafaxine at a really low dose of 37.5 milligrams, and I can titrate up. I have patients take it at night in case they feel a little foggy when they first start it. But more recently, we've started using oxybutynin, which is an anticholinergic medication originally FDA approved for overactive bladder. I use the XL formulation, or you can do 2.5 or 5 milligrams BID. And this, in a study a few years ago, was shown to significantly reduce hot flashes and improve quality of life in a placebo-controlled trial.   So, important aspects of side effects of these medications with SSRIs or SNRIs working in the MUSIC Sexual Health After Cancer Program, sexual health concerns are often an issue, so those drugs can be libido zappers sometimes. But, the biggest side effect I've come across with oxybutynin for patients is dry mouth, and usually that resolves after a little while. So, we've had a lot of success in managing patients' hot flashes with these medications.  Dr. Hope Rugo: That's great and incredibly helpful. And I will say that as we're talking about these issues on this podcast, this is really important for all of our staff and our clinics because most of us don't have a fabulous clinic like the one you've started. But we are managing this with our staff, our APPs, and other areas that our patients are seeing. If everybody has this education, it will really help in the management of symptoms. And I just want to point out that venlafaxine was the first drug to be studied in this area really successful, but that we can use a whole host of different antidepressants. If people have side effects from one another, one may work really well, and generally low doses work well. The oxybutynin was such a very cool study. I think that's a great additional option.    In addition to hot flashes, we also see genitourinary syndrome of menopause, and that's part of what you deal with every day in your clinic, GSM. And this can be not just vaginal dryness, which is bad enough, but also increased infections, painful sex, recurrent bladder infections and also reduced libido, which is a really big issue, we just don't talk about very much. What's the most effective and safe treatment for GSM? And we use a lot of low dose vaginal estrogen and a variety of delivery mechanisms. What are the risk and benefits when patients really need something more?   Dr. Kristin Rojas: GSM, or genitourinary syndrome of menopause, is this newer umbrella term for what we used to call vaginal atrophy. And you're right, it encompasses not only dryness, but all the other changes that can happen to the vulvovaginal mucosa along with anatomic changes to the pelvic floor. This is critically important, I think, that we address these issues or these potential side effects at the time of endocrine therapy prescription because what we have found in our program is that while hot flashes might get better, these symptoms do not get better. And left untreated, they get worse.   And one of the surprising findings that we have presented earlier at another conference this year was that almost half of our patients, when they had their pelvic exam in the program, were also found to have vaginal stenosis. So narrowing and shortening of the vagina, making penetrative sex actually impossible. So it's really not just dryness, but a host of these other symptoms that go along with that. I like to break this down in a really simple way because I know that a lot of providers may be intimidated when patients might bring this up. But I think about it this way. Number 1, eliminate irritants. Number 2, moisturize. Number 3, lubricate. And 4, address the pelvic floor.   Oftentimes when patients present in the MUSIC program, they've been putting a lot of over the counter topical therapies on the vulva and the vagina using intravaginal washes. One of the biggest offenders of some of these symptoms is artificial fragrance, which we can actually develop an allergic reaction to, which manifests as burning and stinging. So these patients may also report burning and stinging in addition to dryness. These offenders can be in all kinds of products. So not only feminine washes, which I don't recommend in our program, but things like bath bombs, bubble bath, toilet paper. And so we kind of go through an inventory of everything that's touching the delicate tissues of the vulva and the vagina and try to back off those products.   The second thing is moisturization. It's important to talk to patients about the difference between moisturization, which I say is for maintenance, and lubricants, which are for PRN use sexual activity. But I tell patients, "lubricants for love." That's how I differentiate the use of these two different types of products because they have different properties. Usually after eliminating irritants, our first step is to start with a non-hormonal moisturizer because there's some really good high-tech non-hormonal moisturizers out there, specifically those containing hyaluronic acid, which pulls moisture from the environment and holds it on the skin. And by using this first—this is my personal opinion—but I think by improving the mucosa a little bit and kind of improving the dryness, maybe even the elasticity a little bit, I think that when patients do have persistent symptoms after using regularly these non-hormonal moisturizers at least three times a week, that adding in a low dose vaginal hormone at that time, instead of putting it on completely atrophic mucosa, you're putting it on kind of like a pretreated mucosa, which I think might decrease systemic absorption.   I'm so glad you brought up vaginal estrogen. I could give an entire talk just on that, so I'd be happy to do that next year for ASCO if anybody wants. But it is very controversial. Historically, there have not been studies showing an increased risk of recurrence with the use of local estrogen therapy, so estrogen in the vulva and the vagina. However, there was a recent study that came out this year that was a large analysis of breast cancer patients receiving different types of hormone therapy. And in a subset analysis of the group who got local vaginal estrogen, just in those patients on aromatase inhibitors, there was a slightly, but statistically significant–according to their analysis–increase in the risk of recurrence. I think there's some issues with this analysis because it was a large study and there's a lot of recall bias and measuring this in patients is really challenging. But I think it's still important to mention because a lot of patients are going to read about those things, these types of studies.   The way I approach it is to start with the lowest dose and I start with infrequent dosing. If patients have persistent symptoms, I start them with once a week or twice a week, which is different from the original pharmacokinetic studies of higher dose estrogens, which showed a bump in their serum estradiol when they used it every night for two weeks. So I actually do the opposite and taper them up. I'll do once a week to twice a week. And usually, patient symptoms are resolved at that point.   But I do want to point out, that's a great option for patients on tamoxifen because mechanistically, as you know, it probably doesn't matter if they have a little bump in their serum estrogen. But for the patients on aromatase inhibitors, we actually have a new kid on the block, a vaginal androgen called prasterone or DHEA. I dose this in the same way, titrate it up. But this can be really helpful for patients on aromatase inhibitors because the ALLIANCE trial showed that for those patients on AIs that their systemic estrogen levels do not increase. And so that's kind of how I manage that discussion. I do think it takes some multidisciplinary collaboration, so I always involve my medical oncology colleagues on this.    Lastly, lubricants. So, everyone seems to be really into using water-based lubricants, but I try to tell patients, unless you're depending on condoms for STD or contraception protection, silicone-based lubricants that are like preservative-free and don't have a lot of those gimmicks or additives, are great—they stay slippery for longer—and there's some really great brands out there. And then for patients who still have persistent pain with sex, we address the pelvic floor, which is either through the use of dilators, referring them to pelvic floor physical therapy, or other sexual devices that we use in the MUSIC program.  Dr. Hope Rugo: This is really helpful, and I think that for many of us in practice, we really want to get the specifics of what you use. I think this prasterone, the idea of DHEA is really very interesting and something that personally I haven't used, but we did use in the distant past before there was an FDA-approved version.   So I guess I have several questions just to ask about the details. So one is, when you prescribe this, do you find it's generally covered by insurance? And when you say low dose, do you mean just try it once a week? And then do you use the estrogen tablets, the brand names are often Yuvafem or Vagifem, we often use those twice a week. How often do you use them and do you use the estrogen ring also? What are the absolute specifics of what you're recommending to these women? And do you feel like sometimes in patients who are developing these symptoms that early use can help avoid the more severe symptoms and therefore reduce the exposure?   And lastly, just to say, that paper which was so interesting about the slightly increased risk of recurrence, I felt was so flawed in terms of what people were using and if they were taking their hormone therapy and risk of recurrence, the risk of the cancer itself, that I really felt like I couldn't make anything out of it in terms of the risk to patients. But I'm really interested in your specific recommendations.  Dr. Kristin Rojas: Thanks for asking about specifics. And I'm happy to give our treatment algorithms here, which we also discussed in our session and we listed in our EdBook manuscript. We do pelvic exams in the MUSIC program and I often find that there's very specific points in the vestibule or the opening of the vagina that are tender and have pain, specifically, what's known as the posterior fourchette, which is the kind of connection between the right and the left side towards the posterior aspect. So, I usually start with a 1% estradiol cream and have patients tap it to the outside and then bring in a dilator and have patients use not only a silicone lubricant, but put some of the estradiol cream on the dilator. And so that brings the product up to the top of the vagina for patients that have some of those anatomic changes that I discussed.   So this is 1 option, and we really don't have a lot of issues with insurance authorization for the cream, just every once in a while. We can also use a 4 microgram or a 10 microgram dose of estradiol, which is a tablet, which are newer options. This is in contrast to the old pharmacokinetic studies that use 25 micrograms. So this is much, much lower. I do run into some prior authorization issues with those because there tend to be newer versions of this. But as you mentioned, the estradiol ring, which I do think is a great option and when you calculate it out, releases a very low dose of estradiol every day. And it's good for patients who want a more low maintenance regimen. The only challenge I've had with that is it's a large rigid ring. And for patients who already have those anatomic changes, it can be really hard to place that in the vagina.   And so, just like you said, early prevention and treatment of these issues can prevent not only anatomic changes, but even potentially the need for exposure for larger doses of hormones. For all of those options, I tend to do it once or twice a week and then can move up. But we sometimes get kind of creative in how we use these options in terms of placing them on the dilator, placing them externally. For patients that have recurrent urinary tract infections, I also have them kind of tap some of the estradiol cream around the urethra as well to improve the urethral and potentially bladder microbiome and decrease risk of recurrent UTIs.  Dr. Hope Rugo: That's really interesting, and I think those specifics are incredibly helpful. We also will check, although I have to say there's no data to support it, the serum estradiol levels in patients who are using more than our minimal amount. We have plenty of studies that have shown that there really isn't systemic estrogen if people are using very low doses. But we will check sometimes, just sometimes people use these topical creams where they get premenopausal levels of estrogen, which of course we don't want. So, this is an incredibly helpful and useful discussion.    One of the other things that happens for these patients and our younger patients, which breast cancer is still increasing in small numbers in younger patients every year, and many of these patients have hormone receptor positive disease. And it just breaks your heart to see a 38-year-old who is planning to get pregnant next month with their new partner who develops a hormone receptor positive breast cancer. and we want to give people all the options they possibly can. We are strong proponents for harvesting eggs and either freezing eggs or embryos before you start treatment. And we figure we always have 2 weeks for breast cancer. We also use ovarian function suppression during chemo just for whatever help it might have.   But then after patients have finished their treatment and they're on hormone therapy, it's a really big issue for women about when they can have a child because we don't want to wait until they're 45. So, you had noted in your article that some women could take a break from endocrine therapy after 18 to 24 months to try and conceive. Can you tell me a little more about that?  Dr. Kristin Rojas: Sure. Well, this aspect of our discussion was very well presented by my colleague, Dr. Terri Woodard from MD Anderson, a reproductive endocrinologist, and she also put together the aspect of this for our manuscript. She talks about how fertility counseling and referral is probably underutilized, but definitely indicated for most of these patients who are of pregnancy age or premenopausal status. And observational data for a long time didn't show that pregnancy after treatment worsened oncologic outcomes. However, patients as well as many providers had reservations.   So, it's been very helpful that we now have a prospective, large, international trial known as the POSITIVE trial, the early results of which came out earlier this year, which showed that women, after 18 to 24 months, could interrupt endocrine therapy and did not have a worsened short-term oncologic outcome. And those are women with early-stage breast cancer. However, there is a concern that many patients do take longer to get pregnant in that age group or after treatment, potentially if they've received chemo. There is a concern about the duration of time that they're not on endocrine therapy afterwards, which might be further clarified in later analyses. So that's my takeaway from that study, which did show us that very helpful, reassuring information. But I think we're still waiting for the long-term data and it's definitely still a very important patient-centered discussion.   Dr. Hope Rugo: This is a really excellent point, and I think that one of the things of a trial like this, which is sort of a registry study, is that we're always going to speak with our feet to some degree. So, if patients have very, very high risk of recurrence and highly proliferative disease, we might not want them to stop at 18 months because their risks are so high early. So, it has to be a risk versus benefit discussion for individual patients, of course. But I think this data was incredibly reassuring.   It was interesting there were some patients who hadn't restarted their endocrine therapy. In the paper in the New England Journal, it told us that some of those patients were still trying to conceive. But one of the things that's going to be really important for these patients is to really make a big effort on the part of our clinical practices to get patients to restart their hormone therapy. It's very hard to do that, as you can imagine, in that setting.    Another area here is monitoring bone health. And I know that's not part of the MUSIC clinic per se because you're really focusing on GSM and other areas that we've just discussed, which are so incredibly important. And it's funny, bone health is silent, right? So, although some patients don't want to take aromatase inhibitors because they're worried about losing further bone density, they don't feel it. So that's, of course, a different kind of a toxicity. But we know that by suppressing ovarian function in young women, we cause a lot of bone loss, and in older women, already in menopause, that this continuous loss of bone increases the risk of fractures, which can be a huge impact on quality of life and even survival in some cases. So, we're really interested in trying to prevent bone demineralization and reducing the risk of fractures. I believe that Matteo Lambertini from Italy discussed this in your paper and that there's a lot of discussion about use of denosumab and zoledronate. I wonder if you could just comment a little bit on that in our last couple of minutes.  Dr. Kristin Rojas: Well, as you said, my colleague Dr. Lambertini put this aspect of our paper together, but he did put together a very nice summary of bisphosphonates and denosumab and separated their use by premenopausal and postmenopausal patients because the data surrounding those patient populations is slightly different or nuanced. But as you mentioned, it is important to monitor these patients' bone density. We have our standard recommendations such as a calcium-enriched diet, resistance and weight-bearing exercise, and vitamin D for patients, for those patients with a vitamin D deficiency or at risk of bone density loss. And so these pharmacologic agents can also help decrease bone mineral density loss and potentially decrease or likely decrease bone recurrences, which, as we know, influences survival. I think he provides a very nice summary of that, as you mentioned.  Dr. Hope Rugo: I think that's so incredibly important. And thank you for really emphasizing the weight-bearing exercise and checking vitamin D and making sure patients are taking vitamin D and at least some calcium. And then, of course, our institution, we work closely with our endocrinologists specializing in bone as well, when issues come up about risk of osteonecrosis of the jaw, and we require dental clearance for everybody starting medication just to make sure that we've reduced risk to the patient. And then when we're trying to think about stopping denosumab and should we bridge with zoledronate to reduce the risk of fracture, we also talk to our bone doc. So it's really important.   And in our last just 1 minute, I know you were thinking of saying something about measuring estrogen in the blood in patients who are using vaginal estrogens. Do you do that?   Dr. Kristin Rojas: Yeah, great question. I'm glad you brought that up. We actually don't routinely do this in the MUSIC program, but it is an important aspect to think about today, because I don't know about where you are, but here in South Florida we have a lot of patients who are receiving therapies outside of the FDA-approved space and these are typically marketed as bioidentical hormones, which is a marketing term. Oftentimes, they'll get either transdermal formulations or pelleted hormone therapy that can result in really high superphysiologic testosterone or estrogen levels. And so we typically, for those patients, do try to get them off those non FDA-approved therapies because the safety of those is unknown.   Dr. Hope Rugo: That's really interesting and so helpful. Yes, I know this whole idea of bioidentical hormones drives me crazy, but I think that's great that you brought that up, actually. We do measure it. Who knows? I think if you're really worried, measuring “Yeah, everybody's hot flashes went away,” it's probably worthwhile checking.   This was such a fabulous conversation. I learned so much. We really appreciate your contribution to the educational manuscript, to the educational program, and your fabulous insights with us today. Thank you so much for participating on the ASCO Daily News Podcast. I think everyone will find this very helpful.   Dr. Kristin Rojas: Thank you so much for having me.   Dr. Hope Rugo: And thank you to you, our listeners, for joining us today. You'll find a link to Dr. Rojas and her colleagues' article in the transcript of this episode and in the 2023 ASCO Educational Book, which features practice-changing oncology research and a wide range of compelling studies on quality and equitable cancer care.    Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Thanks again.    Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    Follow today's speakers:   Dr. Hope Rugo  @hoperugo  Dr. Kristin Rojas  @kristinrojasmd    Follow ASCO on social media:    @ASCO on Twitter    ASCO on Facebook    ASCO on LinkedIn      Disclosures:   Dr. Hope Rugo:  Honoraria: Puma Biotechnology, Mylan, Samsung Bioepis, Chugai Pharma, Blueprint MedicinesConsulting or Advisory Role: Napo PharmaceuticalsResearch Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Genentech, Merck, Odonate Therapeutics, Daiichi Sankyo, Sermonix Pharmaceuticals, AstraZeneca, Gilead Sciences, Ayala Pharmaceuticals, Astellas Pharma, Seattle Genetics, Macrogenics, Boehringer Ingelheim, Polyphor  Dr. Kristin Rojas:   Honoraria: Pacira Pharmaceuticals  Consulting or Advisory Role: Roche Diagnostics, Merck  Research Funding (Inst): Bristol Myers Squibb Foundation       

https://302.buzz/PM-WhatAreYourThoughtsMental health is a crucial aspect of our lives, yet it's often neglected and stigmatized. Dr. Lia Gaggino and her guest, Dr. Carol Chen, will discuss the delicate subject of self-harm and how it pertains to mental health in this episode of Pediatric Meltdown. They examine the numerous causes of young people's self-injury as well as the risk factors and comorbidities that go along with it. You'll learn about Dialectical Behavioral Therapy (DBT), a successful therapy, and how parents can help their kids who engage in self-harming behaviors. For parents, educators, and mental health professionals who want to address self-harm in a helpful and constructive way with advice on coping methods, particularly for adolescents struggling with self-injurious behaviors, this episode will provide significant insights and tools. as technology develops. However, it's crucial to be knowledgeable about mental health concerns and recognize the symptoms of distress in our loved ones and in ourselves. It is essential to establish a forum for open discussion and greater knowledge of the resources accessible. By addressing the underlying causes of self-harm, we can assist teenagers in developing healthier coping strategies and enhance their general wellbeing. So let's all work together to end the stigma associated with mental health problems, get those who need it some care, and encourage one another as we go through this healing process.[00:33 -11:15] Blurring the Lines: The Challenge of Identifying Self-Injury IntentionsSelf-injurious behavior is an umbrella term for actions that result in physical injury to oneself, including suicidal and non-suicidal behaviorsNon-suicidal self-injury specifically refers to behaviors where harm is intentionally caused to one's body for reasons not socially recognized or sanctioned, without the intention of ending one's life Examples of non-suicidal self-injury include cutting, scratching, burning, hair pulling, and punching objectsIt's important to differentiate between suicidal and non-suicidal behaviors for proper risk assessment and intervention, but the distinction can be blurry at times.[11:16 -20:08] Understanding the Psychological Underpinnings of Self-Harm Self-injurious behaviors have diverse reasons and psychological functionsSome teens may self-harm to rebel or seek attention, while others do it out of desperation or depressionSelf-harm is often used as an unhealthy coping mechanism to deal with difficult emotions and to feel in control Some use it to distract themselves or to feel something, as they may feel numb in their daily lives[20:09 -28:50] Childhood Trauma and Self-Harm: Understanding the Link and its Implications for TreatmentSelf-injury is associated with mental health disorders like anxiety, depression, eating disorders, substance use disorder, PTSD, and personality disordersChildhood trauma, especially sexual abuse, is linked to an increase in cutting behavior Borderline personality disorder includes self-harm as one of its nine criteriaTeenagers may exhibit borderline personality traits, including cutting, but are not diagnosed with personality disorders due to their developing personalities[28:51-40:50] How Medications Can Help Heal Trauma and Unleash Inner Happiness SSRIs can be used to treat anxiety and depressionAlpha agonists like Guanfacine or Clonidine can be helpful for impulsivity and trauma responseNaltrexone can be used for repeated self-injurious...

To get a hold of my books, you can find Memorizing Pharmacology Second Edition HERE or Memorizing Pharmacology Mnemonics HERE In this episode, I go over how you can use the POP CAN mnemonic to remember the alpha agonists and what that means for pharmacology indications and adverse effects.

Welcome all to IS PHARMACOLOGY DIFFICULT Podcast! I am Dr Radhika Vijay. In today's episode I begin my words with the importance of beginnings irrespective to their relevance to time. It is always a good time to begin new, to start afresh!! So all smiles for your wonderful efforts and starts for today! Today's discussion is all about alpha 2 receptor agonists especially highlighted example of the major drug "Clonidine". I will cover it's importance, mechanism, route of administration, ADME profile, effects, uses, adverse effects, etc. In the end wishing fruitful beginnings to your endeavours in order to achieve your set goals and targets and make your wishes true this year '23!! For all the updates and latest episodes of my podcast, please visit www.ispharmacologydifficult.com where you can also sign up for a free monthly newsletter of mine. It actually contains lot of updates about the medical sciences, drug information and my podcast updates also. You can follow me on different social media handles like twitter, insta, facebook and linkedin. They all are with same name "IS PHARMACOLOGY DIFFICULT". If you are listening for the first time, do follow me here, whatever platform you are consuming this episode, stay tuned, do rate and review on ITunes, Apple podcasts, stay safe, stay happy, stay enlightened, Thank you!! You can access various links via-https://linktr.ee/ispharmacologydifficult Please leave Review on Apple podcasts! Connect on Twitter & Instagram! My books on Amazon & Goodreads!

Welcome all to IS PHARMACOLOGY DIFFICULT Podcast! I am Dr Radhika Vijay.In today's episode I begin my words with the importance of beginnings irrespective to their relevance to time. It is always a good time to begin new, to start afresh!!So all smiles for your wonderful efforts and starts for today!Today's discussion is all about alpha 2 receptor agonists especially highlighted example of the major drug "Clonidine". I will cover it's importance, mechanism, route of administration, ADME profile, effects, uses, adverse effects, etc.In the end wishing fruitful beginnings to your endeavours in order to achieve your set goals and targets and make your wishes true this year '23!!For all the updates and latest episodes of my podcast, please visit www.ispharmacologydifficult.com where you can also sign up for a free monthly newsletter of mine. It actually contains lot of updates about the medical sciences, drug information and my podcast updates also.You can follow me on different social media handles like twitter, insta, facebook and linkedin. They all are with same name "IS PHARMACOLOGY DIFFICULT".If you are listening for the first time, do follow me here, whatever platform you are consuming this episode, stay tuned, do rate and review on ITunes, Apple podcasts, stay safe, stay happy, stay enlightened, Thank you!!You can access various links via-https://linktr.ee/ispharmacologydifficultPlease leave Review on Apple podcasts!Connect on Twitter & Instagram!My books on Amazon & Goodreads!

What other medications can we offer to our patients with BPD? This episode discusses some novel medication approaches used in borderline personality disorder, including omega-3 fatty acids, methylphenidate, clonidine, doxazosin, memantine, and oxytocin.  Faculty: Paul Links, M.D.  Host: Jessica Diaz, M.D. Learn more about Premium Membership here Earn 0.5 CMEs: Pharmacologic Management of BPD: Recent Developments Omega-3 Fatty Acids, Methylphenidate, Clonidine, Doxazosin, Memantine, and Oxytocin for BPD

Welcome to PICU Doc On Call, A Podcast Dedicated to Current and Aspiring Intensivists. I'm Pradip Kamat and I'm Rahul Damania. We are coming to you from Children's Healthcare of Atlanta - Emory University School of Medicine. Welcome to our Episode about a 14- year- old female who presented with hypotension after a suicide attempt. Here's the case: A 14 yo F with PMH of depression and oppositional defiant disorder presents with dizziness. Her mother states she was in her normal state of health when on the day of admission she noticed the patient to be dizzy, slurring speech, and pale. The mother became very concerned about the dizziness as the patient was stumbling and a few hours prior to presentation, became increasingly sleepy. The patient does have a history of depression and is controlled on sertraline. Other medications in the home include Metformin, Amlodipine, and Clonidine. The patient denies ingesting any substance. She does have a prior attempt two years prior, after an argument with her mother; however, her mother was able to “stop” her prior to the attempt. She presents to the ER via EMS. Her vital signs are notable for HR 50 bpm with occasional PACs and non-conducted QRS complexes on telemetry; BP of 75/40. A physical exam is notable for AMS and GCS of 10. She is noted to have clear breath sounds, with a cardiac exam notable for slowed and delayed pulses. Initial laboratory work is notable for serum glucose 180 mg/dL and B HCG negative. Initial resuscitation is begun with IV fluids and atropine. Serum acetaminophen and ASA levels are sent and upon stabilization, the patient presents to the PICU for admission. To summarize key elements from this case, this patient has: A history of depression with prior attempt An acute bout of altered mental status Bradycardia, hypotension, and hyperglycemia. All of which brings up a concern for an acute ingestion Let's take a step back and talk about the approach to ingestions in the PICU. What are key aspects to consider in the work-up of these patients? History and physical are key: Stratifying acute or chronic ingestions Baseline prescription medications a patient may be taking or have access to in the household Whether the ingestion involves a single drug or co-ingestants are all first steps in evaluating your patient. In an undifferentiated patient, management is paramount. Initial management is focused on pattern recognition and acute stabilization. A brief initial screening examination should be performed on all patients to identify immediate measures required to stabilize and prevent deterioration of the patient. Assess the airway, vital signs, mental status, pupil size, and skin temperature and moisture. These components of your physical exam should help allude to a toxidrome, and these syndromes are frequently tested on board examinations. Any time a patient has hypotension and bradycardia other drugs that should be considered include beta blockers, digoxin, clonidine, as well as ingestion of barbiturates, opioids, and even benzodiazepines. What are some diagnostic studies you will want to send immediately in a patient with suspected ingestion? Immediate diagnostic studies to be performed include pulse oximetry, continuous cardiac monitoring, an electrocardiogram (ECG), and a capillary glucose measurement (in altered patients). Intravenous (IV) access should be obtained in all cases of serious ingestion. You also want to send beta-hcg and acetaminophen and salicylate levels. an extended toxicology screen may be required on a case-by-case basis. One study found detectable serum acetaminophen concentrations in 9.6 percent of all overdose patients; almost one-third of this subset denied ingestion of acetaminophen. Now that you've focused on ABCs are there more detailed laboratory studies to send in patients with toxidromes? Symptomatic patients and those with an unreliable or unknown history should, at a minimum, undergo...

Marshall McLuhan famously said "The medium is the message." That's where we begin this week.You have probably seen the headlines in recent weeks, "Philadelphia drug supply polluted with Veterinary Tranquilizer." As our self-created "opioid epidemic" continues, we can expect similar drugs to pop up, boogie men for the government and the press to blame for a problem which is designed into the system. Xylazine is a sedative drug which is an analogue (synthesized version) of Clonidine. It can be purchased without a prescription in most US states and is now making its way into the drug supply of many big cities. The first time I heard of Xylazine was in 2012 in this article from the Journal of Urban Health. Back then it was reported to be a huge problem across Puerto Rico, leading to abscessed skin infections and terrible scarring or even death. Now its showing up across the US.  A paper published in April 2022 in the Journal of Drug & Alcohol Dependence showed rates of Xylazine in streets drugs is on the rapid rise.Always test your drugs. The Dr. Junkie Show does not offer medical advice. Consult your doctor; I'm not them. 

Effects of magnesium sulphate on the onset time of rocuronium is this BJANcast's main theme with Dr. Sigmar Áurea Cabral The article we based our interview is "Effect of adding clonidine to lidocaine on ocular hemodynamics during sub-Tenon's anesthesia: randomized double-blind study". You can download this and other articles directly from BJAN's website. BJAN helps to improve the research and brazilian science. #citeBJAN #joinBJAN Social Networks: bjan-sba.org Instagram Facebook LinkedIn Twitter

Join medical student Rilee Racine and Dr. Brian Stansfield, a neonatologist at the Children's Hospital of Georgia discuss Neonatal Opioid Withdrawal Syndrome, also known as NOWS.  After listening to this podcast, learners should be able to: Define neonatal opioid withdrawal syndrome Apply knowledge of signs and symptoms of NOWS to recognize these infants early Demonstrate general understanding of non-pharmacologic vs. pharmacologic management indications Recall the long term effects of NOWS and utilize this information to care for these infants long-term Educate families on clinical symptoms, management, and potential complications of NOWS Peer Review by Dr. Rebecca Yang and Dr. Amy Thompson Free CME Credit (requires sign-in): LINK COMING SOON Thank you for listening to this episode from the Department of Pediatrics at the Medical College of Georgia. If you have any comments, suggestions, or feedback- you can email us at mcgpediatricpodcast@augusta.edu. Remember that all content during this episode is intended for informational and educational purposes only. It should not be used as medical advice to diagnose or treat any particular patient. Clinical vignette cases presented are based on hypothetical patient scenarios. References: Anbalagan S, Mendez MD. Neonatal Abstinence Syndrome. 2020 Oct 1. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–. PMID: 31855342. Armbruster, Debra PhD, APRN-CNP, NNP-BC, CPNP-PC, C-ELBW; Schwirian, Caitlyn PharmD; Mosier, Ashley MS, RN, CNL; Tam, Wai-Yin Mandy PharmD, BCPS, BCCCP; Prusakov, Pavel PharmD, BCPS, BCPPS Neonatal Abstinence Syndrome and Preterm Infants, Advances in Neonatal Care: March 05, 2021 - Volume Publish Ahead of Print - Issue - doi: 10.1097/ANC.0000000000000858 Finnegan LP. Neonatal abstinence syndrome: assessment and pharmacotherapy. In: Nelson N, editor. Current therapy in neonatal-perinatal medicine. 2 ed. Ontario: BC Decker; 1990. Jansson, Lauren M. MD. Neonatal abstinence syndrome. Uptodate. (2020). Johnson MR, Nash DR, Laird MR, Kiley RC, Martinez MA. Development and implementation of a pharmacist-managed, neonatal and pediatric, opioid-weaning protocol. J Pediatr Pharmacol Ther. 2014 Jul;19(3):165-73. doi: 10.5863/1551-6776-19.3.165. PMID: 25309146; PMCID: PMC4187529. Maguire, Denise J, PhD,R.N., C.N.L., Taylor, Susan, MSW,L.C.S.W.-C., C.M.A., Armstrong, K., PhD., Shaffer-Hudkins, E., Germain, A. M., M.D., Brooks, Sandra S,M.D., M.P.H., . . . Clark, L. (2016). Long-term outcomes of infants with neonatal abstinence syndrome: NN. Neonatal Network, 35(5), 277-286. doi:http://dx.doi.org/10.1891/0730-0832.35.5.277 Mangat, A. K., Schmölzer, G. M., & Kraft, W. K. (2019). Pharmacological and non-pharmacological treatments for the Neonatal Abstinence Syndrome (NAS). Seminars in fetal & neonatal medicine, 24(2), 133–141. https://doi.org/10.1016/j.siny.2019.01.009 Merhar SL, Ounpraseuth S, Devlin LA, Poindexter BB, Young LW, Berkey SD, Crowley M, Czynski AJ, Kiefer AS, Whalen BL, Das A, Fuller JF, Higgins RD, Thombre V, Lester BM, Smith PB, Newman S, Sánchez PJ, Smith MC, Simon AE; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT NEONATAL RESEARCH NETWORK AND THE NIH ENVIRONMENTAL INFLUENCES ON CHILD HEALTH OUTCOMES (ECHO) PROGRAM INSTITUTIONAL DEVELOPMENT AWARDS STATES PEDIATRIC CLINICAL TRIALS NETWORK. Phenobarbital and Clonidine as Secondary Medications for Neonatal Opioid Withdrawal Syndrome. Pediatrics. 2021 Mar;147(3):e2020017830. doi: 10.1542/peds.2020-017830. PMID: 33632932; PMCID: PMC7919109. Protecting Our Infants Act of 2015, H.R, 1462, 114th Cong. (2015-2016).  Sarka Lisonkova, Lindsay L. Richter, Joseph Ting, Giulia M. Muraca, Qi Wen, Azar Mehrabadi, Sheona Mitchell-Foster, Eugenia Oviedo-Joekes and Janet Lyons. Pediatrics August 2019, 144 (2) e20183664; DOI: https://doi.org/10.1542/peds.2018-3664 Siegler R., Saffran J., Eisenberg N., Deloache, J., & Gershoff, E. (2017). How Children Develop (5th ed.). NY, NY, USA: Macmillan Learning.  Stephen W. Patrick, Wanda D. Barfield, Brenda B. Poindexter and COMMITTEE ON FETUS AND NEWBORN, COMMITTEE ON SUBSTANCE USE AND PREVENTION. Neonatal Abstinence Withdrawal Syndrome. Pediatrics November 2020, 146 (5) e2020029074; DOI: https://doi.org/10.1542/peds.2020-029074 Patrick SW, Barfield WD, Poindexter BB; COMMITTEE ON FETUS AND NEWBORN, COMMITTEE ON SUBSTANCE USE AND PREVENTION. Neonatal Opioid Withdrawal Syndrome. Pediatrics. 2020 Nov;146(5):e2020029074. doi: 10.1542/peds.2020-029074. PMID: 33106341. Zimmermann, U., Rudin, C., Duò, A. et al. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. Eur J Pediatr 179, 141–149 (2020). https://doi.org/10.1007/s00431-019-03486-6

I read from clonidine to close.     The word of the episode is "clonk".       Featured in a Top 10 Dictionary Podcasts list! https://blog.feedspot.com/dictionary_podcasts/   dictionarypod@gmail.com https://www.facebook.com/thedictionarypod/ https://twitter.com/dictionarypod https://www.instagram.com/dictionarypod/ https://www.patreon.com/spejampar 917-727-5757

As always, feel free to send us questions, comments or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through instagram or twitter, @nicupodcast. Or contact Ben and Daphna directly via their twitter profiles: @drnicu and @doctordaphnamd. Papers discussed in today's episode are listed and timestamped below.enjoy!01:50 - Reviewing recordings of neonatal resuscitation with parents. https://fn.bmj.com/content/106/4/34610:55 - Associations between family presence and neonatal intubation outcomes: a report from the National Emergency Airway Registry for Neonates: NEAR4NEOS https://fn.bmj.com/content/106/4/39219:28 - A Retrospective Review Following the Addition of Clonidine to a Neonatal Abstinence Syndrome Treatment Algorithm. https://www.frontiersin.org/articles/10.3389/fped.2021.632836/full25:03 - Trial of aerosolised surfactant for preterm infants with respiratory distress syndrome. https://fn.bmj.com/content/early/2021/06/09/archdischild-2021-32164530:15 - Interface leakage during neonatal CPAP treatment: a randomised, cross-over trial. https://fn.bmj.com/content/early/2021/06/28/archdischild-2021-32157933:55 - Changes in Physicians' Perceptions and Practices on Neonatal Pain Management Over the Past 20 Years. A Survey Conducted at Two Time-Points. https://www.frontiersin.org/articles/10.3389/fped.2021.667806/full39:02 - The Experience of Housing Needs Among Families Caring for Children With Medical Complexity. https://pediatrics.aappublications.org/content/148/1/e202001893747:10 - Home Visiting for NICU Graduates: Impacts of Following Baby Back Home. https://pediatrics.aappublications.org/content/148/1/e202002939752:25 - An Infant Carrier Intervention and Breastfeeding Duration: A Randomized Controlled Trial. https://pediatrics.aappublications.org/content/148/1/e202004971756:37 - Severity of Bronchopulmonary Dysplasia Among Very Preterm Infants in the United States. https://pediatrics.aappublications.org/content/148/1/e202003000758:41 - Human milk feeding and cognitive outcome in preterm infants: the role of infection and NEC reduction. https://www.nature.com/articles/s41390-021-01367-z61:27 - Validity of Random Triglyceride Levels in Infants Receiving Parenteral Nutrition. https://www.frontiersin.org/articles/10.3389/fped.2021.601915/full62:40 - Degree of ventriculomegaly predicts school-aged functional outcomes in preterm infants with intraventricular hemorrhage. https://www.nature.com/articles/s41390-021-01631-2

Patrick Finan, PhD, is an Associate Professor of Psychiatry and Behavioral Science at Johns Hopkins University. We delve into the interplay between pain and sleep, but first by breaking down pain and sleep on their own. Sleep Duration as a Risk Factor for Cardiovascular Disease (PMID: 21286279) Sleep Duration and Heart Attacks (PMID: 31488267) Clonidine disrupts REM sleep (PMID: 26678391) Dr. Patrick Finan research publications Sponsor: Larry Keller Disability Insurance

Podcast summary of articles from the January 2021 edition of the Journal of Emergency Medicine from the American Academy of Emergency Medicine.  Topics include shoulder dislocations, Phenytoin toxicity, Clonidine Toxicity, STEMI in the COVID era, spinal cord injury and board review on angioedema.  Guest speaker is Dr. Paul Koscumb.

Show notes at pharmacyjoe.com/episode587. In this episode, I ll discuss the effects of haloperidol and clonidine on the resolution of delirium in critically ill patients. The post 587: What are the effects of haloperidol and clonidine on resolution of delirium in critically ill patients? appeared first on Pharmacy Joe.

Did you know that a single tablet from the medicine cabinet or ingestion of a teaspoon of a liquid  household product can potentially cause morbidity and even death in a child?    Dr. Jennifer Tucker, a Pediatric Emergency Physician, joins Dr. Rebecca Yang and Pediatric Resident James Davis to discuss the evaluation and management for specific common but dangerous household medications and substances in the household.   Review the basic assessment skills and evaluation for a child presenting with a potential toxic ingestion  Discuss the role of decontamination, diagnostic options, treatment and monitoring for toxic ingestions  Medications reviewed: Calcium Channel Blockers, Clonidine, Oral Hypoglycemics  Household products reviewed are those that contain toxic alcohols, benzocaine, Imidazoline, Camphor, and methylsalycylate  Anticipatory guidance to families regarding potential exposure/ingestion    Special thanks to Dr. George Hsu and Dr. Eric Ring for peer reviewing this episode.    Check out our website for detailed show-notes: https://www.augusta.edu/mcg/pediatrics/residency/podcast.php Questions, comments, or feedback? Please email us at mcgpediatricpodcast@augusta.edu    References: Deadly Pediatric Poisons: Nine Common Agents that Kill at Low Doses. MichaelJB, Sztajnkrycer MD. Emerg Med Clin North Am. 2004;22(4):1019–1050 Toxic Ingestions: Initial Management. Courtney W. Mangus, Therese L. Canares. Pediatrics in Review Apr 2018, 39 (4) 219-221 Tucker MD, Jennifer. "One Pill (Or Sip) Can Kill." MCG Pediatric Grand Rounds Presentation. Augusta, Georgia. July 15,2016.  

We take you through the story of rational drug discovery that lead to the approval of guanfacine and clonidine for ADHD, and share some tips on how to use them. And the word of the day: Dyssymbole. Published On: 10/26/2020 Duration: 19 minutes, 55 seconds Article Referenced: "Guanfacine ER for Adults With ADHD?" The Carlat Psychiatry Report, October 2020 Got feedback? Take the podcast survey.  

Podcast summary of articles from the July 2020 edition of the Journal of Emergency Medicine from the American Academy of Emergency Medicine.  Topics include headache, CAR T cell therapy, clonidine toxicity, 4 factor PCC, and board review on high risk airway management.  Guest speaker is Dr. Skyler Lentz.

Dr. Alan Kazen is a board certified addiction specialist and the medical director at Calvary Recovery Center in Phoenix, AZ. Listen in as Dr. Kazen shares his practical advice, expertise and clinical insights gathered over a long and successful career helping people in their recovery. Topics of discussion include harm prevention (Naloxone, Hep C, and Fentanyl testing), acute rescue meds (Clonidine, Lucemyra, etc), the importance of mood stabilization for recovery, and how to increase the probability of long term recovery.

Bom dia, boa tarde, boa noite! Esse é mais um podcast do Medicina do Conhecimento. Ciência e informação a qualquer momento, em todo lugar. Eu sou Pablo Gusman, o Anestesiador. E como compartilhar é multiplicar segue uma pílula, dica rápida para aumentar seu conhecimento. Antes eu gostaria de avisar que você usuário de smartphones androides pode baixar o app Medicina do Conhecimento na sua loja Google Play para ouvir a nossa rádio web e interagir conosco no seu momento. Basta procurar por medicinadoconhecimento. Digite todas as palavras juntas! Vamos lá aumentando nosso mundo do conhecimento. A clonidina tem sido usada como droga adjuvante de anestésicos locais em várias técnicas regionais para prolongar a duração dos bloqueios moter e sensitivo. Uma revisão sistemática de Elia e colaboradores no jornal Regional Anesthesia Pain Medicine mostrou que a duração do bloqueio motor e sensitivo foi prolongada por 47 minutos em média quando a clonidina foi adicionada a anestésicos locais intratecais. Contudo, o estudo não divulgou uma dose ideal e incluiu uma faixa de dosagem ampla de 15 a 150 μg. Na publicação de Rhee no Acta Anaesthesiologica Scandinavica, uma dose de 3 μg/kg de clonidina endovenosa administrada imediatamente após o bloqueio espinhal mostrou o prolongamento do bloqueio por aproximadamente 60 minutos sem efeitos colaterais adversos perceptíveis. Além disso, deve-se notar que, embora conheçamos o mecanismo de ação da clonidina na técnica neuroaxial, não há um mecanismo de ação estabelecido da clonidina no bloqueio de nervo periférico. Um ensaio clínico randomizado duplo-cego de Duma no British Journal of Anaesthesia investigou os efeitos da clonidina no prolongamento da duração do bloqueio do plexo braquial e axilar e mostrou que não houve diferença na duração do bloqueio com ou sem clonidina. Baixe os arquivos no nosso canal do Telegram Medicina do Conhecimento! O link é t.me/medconhecimento ou abra seu telegram e busque por Medicina do Conhecimento. A qualquer momento e em todo lugar, escute a rádioweb no www.medicinaconhecimento.com.br Escolha sua plataforma e ouça mais podcasts. Siga pelo Spotify, Deezer, Itunes, Google Podcasts, Soundcloud, Youtube e mais uma dezena de agregadores de podcast. Na medicina do conhecimento, você escolhe o player da sua preferência. É muito importante seu feedback. Compartilhe nas suas redes e deixe seu like. Isso aumenta a divulgação do projeto. Além disso, você pode entrar em contato conosco e sugerir o próximo tema! Fique ligado nas redes sociais Twitter, Facebook e Instagram Medicina do Conhecimento, afinal compartilhar é multiplicar! Murphy DB, McCartney CJ, Chan VW. Novel analgesic adjuncts for brachial plexus block: a systematic review. Anesthes Analg. 2000;90(5):1122-1128. Elia N, Culebras X, Mazza C, Schiffer E, Tramer MR. Clonidine as an adjuvant to intrathecal local anesthetics for surgery: systematic review of randomized trials. Reg Anesth Pain Med. 2008;33(2):159-167. Rhee K, Kang K, Kim J, Jeon Y. Intravenous clonidine prolongs bupivacaine spinal anesthesia. Acta Anaesthesiol Scand. 2003;47(8):1001-1005. Duma A, Urbanek B, Sitzwohl C, Kreiger A, Zimpfer M, Kapral S. Clonidine as an adjuvant to local anesthetic axillary brachial plexus block: a randomized, controlled study. Br J Anaesth. 2005;94(1):112-116.

What you don't know about these two blood pressure drugs might hurt you. In this episode, Dr. Tonya will tell you what you might not know about two drugs that are commonly used to treat severe hypertension. Here is what everybody ought to know about Clonidine and Hydralazine. The information in this podcast is based on the current hypertension guidelines, the Physician Desk Reference, and Dr. Tonya's clinical experiences. This is not medical advice. Consult with your doctor or health care provider for any medical advice.Click here to see how to use a home blood pressure monitor and log.You can purchase an Omron Blood Pressure Monitor from any big box store or pharmacy. Click here for purchase online.About the host: Dr. Tonya is a clinical research scientist at the University of Alabama at Birmingham, Alabama, where she holds various positions. She spent the past decade studying home blood pressure monitoring and tracking, medication adherence, readiness, and confidence to change lifestyle behaviors. She is the author of six first-authored publications in scientific journals. She has collaborated with her colleagues on three published studies with the finding from the landmark Systolic Blood Pressure Intervention (SPRINT) Trial. You can read her peer-reviewed research studies at https://www.ncbi.nlm.nih.gov/pubmed/?term=TONYA+BREAUX-SHROPSHIRE.About the podcast: Dr. Tonya has created this blog and podcast for everyday people to learn what everybody ought to know about hypertension. Uncontrolled hypertension is a leading cause of stroke, kidney failure, heart attack, congestive heart failure, and other poor cardiovascular outcomes. With this podcast, Dr. Tonya hopes to decrease health disparity and improve health literacy in the cardiovascular space. Before you can take control of your health and health care costs, you have to invest your time in learning what you ought to know about hypertension. Hit the subscribe button to get upcoming episodes immediately when released. Share Hypertension Resistant to Treatment blog and podcast with any one person who would benefit from it.If you enjoyed the podcast, please share and consider leaving a 5-star rating and leave a short review below.Resources:Hypertension GuidelinesPhysician Desk Reference Voiceover Intro and soon to be outro done by Mr. Willie Breaux, Jr.Song: Forget Your Feet; Artist: Tayler Watts; Licensed to YouTube by Epidemic Sound; Epidemic Sound PublishingDisclaimer: This podcast is for information purposes only and should not be used as medical advice. It is for educational purposes only and was not intended to replace medical advice. Dr. Tonya has provided this content based on her research training and clinical and research knowledge. Consult your health care provider for medical advice.

Show notes at pharmacyjoe.com/episode461. In this episode, I’ll discuss why beta-blockers should be tapered before clonidine. The post 461: Why should beta-blockers be tapered before clonidine? appeared first on Pharmacy Joe.

Anand Swaminathan on Lemierre's syndrome, Emily Austin on clonidine toxicity, Brit Long on myths of routine coagulation panel testing, Hans Rosenberg and Michael Ho on reversal of anticoagulation, Sheldon Cheskes on mechanical CPR... The post EM Quick Hits 8 Lemierre’s Syndrome, Clonidine Toxicity, Routine Coag Panel, Anticoagulation Reversal, Mechanical CPR appeared first on Emergency Medicine Cases.

Author:  Julian Orenstein, MD Educational Pearls:   Severe clonidine ingestion can present as a fluctuating mental status between typically accompanied by changes in vital signs (hypotension/bradycardia) Respiratory depression requiring intubation is not uncommon   References Isbister GK, Heppell SP, Page CB, Ryan NM. Adult clonidine overdose: prolonged bradycardia and central nervous system depression, but not severe toxicity. Clin Toxicol (Phila). 2017 Mar;55(3):187-192. doi: 10.1080/15563650.2016.1277234. Epub 2017 Jan 20. PubMed PMID: 28107093. Spiller HA, Klein-Schwartz W, Colvin JM, Villalobos D, Johnson PB, Anderson DL. Toxic clonidine ingestion in children. J Pediatr. 2005 Feb;146(2):263-6. PubMed PMID: 15689921. Summarized by Will Dewispelaere, MS3 | Edited by Erik Verzemnieks, MD

Clonidine is classified as an antihypertensive. Clonidine pharmacology involves having agonist activity at central alpha 2 receptors. This leads to lower sympathetic outflow and a reduction in blood pressure. Clonidine has numerous reported uses in addition to its antihypertensive effect. It can potentially be used for ADHD, menopausal type symptoms, and opioid withdrawal. Clonidine has historically been on the Beers' list of drugs as it can cause some CNS side effects like sedation, dizziness, and rarely delirium. Clonidine is unique in the antihypertensive class as it does have a patch formulation. Because of the blood pressure lowering effect of clonidine, we have to be aware of patients who report dizziness. Monitoring is critical. Clonidine can also lower heart rate and contribute to dry mouth. Keep an eye out for drugs that can have a cumulative effect on these symptoms. Drugs like beta-blockers, non-DHP CCB's, and digoxin can all have a cumulative effect with clonidine and lower pulses. Monitoring is important.

Show notes at pharmacyjoe.com/episode358. In this episode I ll: 1. Discuss an article about exposure to antibiotics and development of new resistance. 2. Answer the drug information question Can naloxone reverse oversedation from clonidine toxicity?” 3. Share a tip for responding to medical emergencies. The post 358: Antibiotic exposure and development of resistance, naloxone for clonidine toxicity, and a tip for responding to medical emergencies appeared first on Pharmacy Joe.

Participants: • Master of Ceremonies and CNS Resident Committee Chair: Martina Stippler, MD • Author/Presenter: Joe Abdel Hay, MD • Discussants and CNS Resident Fellows: Kivanc Atesok, MD and Rimal Dossani, MD

Dr. Rosenblum reads and reviews ASRAs Chronic Pain Guidelines and provides a commentary.   Download the PainExam App for iPhone and Android References https://journals.lww.com/rapm/Fulltext/2018/07000/Consensus_Guidelines_on_the_Use_of_Intravenous.11.aspx       Subscribe to our mailing list * indicates required Email Address  *                         DISCLAIMER: Doctor Rosenblum IS HERE SOLELY TO EDUCATE, AND YOU ARE SOLELY RESPONSIBLE FOR ALL YOUR DECISIONS AND ACTIONS IN RESPONSE TO ANY INFORMATION CONTAINED HEREIN. This podcasts is not intended as a substitute for the medical advice of physician to a particular patient or specific ailment.  You should regularly consult a physician in matters relating to yours or another's health.  You understand that this podcast is not intended as a substitute for consultation with a licensed medical professional.    Copyright © 2018 QBazaar.com, LLC  All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, recording or otherwise, without the prior written permission of the author.    

Dr. Rosenblum review the lates ASRA Guidelines for Ketamine use in the treatment of chronic pain.    AnesthesiaExam Podcast App For iPhone and Android   Subscribe to our mailing list * indicates required Email Address *   Reference  https://journals.lww.com/rapm/Fulltext/2018/07000/Consensus_Guidelines_on_the_Use_of_Intravenous.11.aspx DISCLAIMER: Doctor Rosenblum IS HERE SOLELY TO EDUCATE, AND YOU ARE SOLELY RESPONSIBLE FOR ALL YOUR DECISIONS AND ACTIONS IN RESPONSE TO ANY INFORMATION CONTAINED HEREIN. This podcasts is not intended as a substitute for the medical advice of physician to a particular patient or specific ailment. You should regularly consult a physician in matters relating to yours or another’s health. You understand that this podcast is not intended as a substitute for consultation with a licensed medical professional. 
 Copyright © 2018 QBazaar.com, LLC All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, recording or otherwise, without the prior written permission of the author.      

Mogens Ydemann and Arash Afshari discuss their work with clonidine as a treatment for the prevention of postoperative agitation in children.

Mogens Ydemann and Arash Afshari discuss their work with clonidine as a treatment for the prevention of postoperative agitation in children.

How do you approach the child who may be altered?   Altered mental status in children can be subtle.  Look for age-specific behaviors that range from irritability to anger to sleepiness to decreased interaction. In the altered child, anchoring bias is your biggest enemy.  Keep your mind open to the possibilities, and be ready to change it, when new information becomes available. For altered adults, use AEIOU TIPS (Alcohol-Epilepsy-Insulin-Overdose-Uremia-Trauma-Infection-Psychosis-Stroke). Try this for altered children: remember that they need their VITAMINS! V – Vascular (e.g. arteriovenous malformation, systemic vasculitis) I – Infection (e.g. meningoencephalitis, overwhelming alternate source of sepsis) T – Toxins (e.g. environmental, medications, contaminated breast milk) A – Accident/abuse (e.g. non-accidental trauma, sequelae of previous trauma) M – Metabolic (e.g. hypoglycemia, DKA, thyroid disorders) I – Intussusception (e.g. the somnolent variant of intussusception, with lethargy) N – Neoplasm (e.g. sludge phenomenon, secondary sepsis, hypoglycemia from supply-demand mismatch) S – Seizure (e.g. seizure and its variable presentation, especially subclinical status epilepticus)   Case One: Sleepy Toddler 16-month-old who chewed on his grandmother's clonidine patch Clonidine is an alpha-2 agonist with many therapeutic indications including hypertension, alcohol withdrawal, smoking cessation, perimenopausal symptoms.  In children specifically, clonidine is prescribed for attention deficit hyperactivity disorder, spasticity due to cerebral palsy and other neurologic disorders, and Tourette’s syndrome. The classic clonidine toxidrome is altered mental status, miosis, hypotension, bradycardia, and bradypnea.  Clonidine is on the infamous list of “one pill can kill”. Treatment is primarily supportive, with careful serial examinations of the airway, and strict hemodynamic monitoring. Naloxone can partially counteract the endogenous opioids that are released with clonidine's pharmacodynamics. Start with the usual naloxone dose of 0.01 mg/kg, up to the typical adult starting dose is 0.4 mg. In clonidine overdose, however, you may need to increase the naloxone dose (incomplete and variable activity) up to 0.1 mg/kg.  Titrate to hemodynamic stability and spontaneous respirations, not full reversal of all CNS effects.   Case Two: In Bed All Day A 7-year-old with fever, vomiting, body aches, sick contacts.  Altered on exam. Should you get a CT before LP? If you were going to perform CT regardless, then do it. Adult guidelines: age over 60, immunocompromised state, history of central nervous system disease, seizure within one week before presentation, abnormal level of consciousness, an inability to answer two consecutive questions correctly or to follow two consecutive commands, gaze palsy, abnormal visual fields, facial palsy, arm drift, leg drift, and abnormal language. Children: if altered, and your differential diagnosis is broad (especially if you may suspect tumor, bleed, obvious abscess). Influenza is often overlooked as a potential cause of altered mental status.  Many authors report a broad array of neurological manifestations associated with influenza, such as altered mental status, seizures, cranial nerve abnormalities, hallucinations, abnormal behavior, and persistent irritability.  All of this is due to a hypercytokinemic state, not a primary CNS infection.   Case Three: Terrible Teenager 14-year-old brought in for "not listening" and "acting crazy"; non-complaint on medications for systemic lupus erythematosus (SLE). SLE is rare in children under 5. When school-age children present with SLE, they typically have more systemic signs and symptoms.  Teenagers present like adults.  All young people have a larger disease burden with lupus, since they have many more years to develop complications. Lupus cerebritis: high-dose corticosteroids, and possibly IV immunoglobulin.  Many will need therapeutic plasma exchange (TPE), a type of plasmapheresis.   Summary In altered mental status, keep your differential diagnosis open Pursue multiple possibilities until you are able to discard them Be ready to change your mind completely with new information Make sure your altered child gets his VITAMINS (Vascular, Infectious, Toxins, Accident/Abuse, Metabolic, Intussusception, Neoplasm, Stroke)   References Beckman HB, Frankel RM. The effect of physician behavior on the collection of data. Ann Intern Med 1984; 101:692. Fujita K, Nagase H, Nakagawa T et al. Non-convulsive seizures in children with infection-related altered mental status. Pediatrics International. 2015; 57(4):659–664. Gallagher J, Luck RP, Del Vecchio M. Altered mental status – a state of confusion. Paediatr Child Health. 2010 May-Jun; 15(5): 263–265. Hasbun R, Abrahams J, Jekel J, Quagliarello VJ. Computed tomography of the head before lumbar puncture in adults with suspected meningitis. N Engl J Med. 2001; 345(24):1727-33. Oliver WJ, Shope TC, Kuhns LR. Fatal Lumbar Puncture: Fact Versus Fiction—An Approach to a Clinical Dilemma. Pediatrics. 2003; 112(3) Schwartz J et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue. Journal of Clinical Apheresis. 2013; 28:145–284. Zorc JJ. A lethargic infant: Ingestion or deception? Pediatr Ann 2000; 29: 104–107   This post and podcast are dedicated to Teresa Chan, HBSc, BEd, MD, MS, FRCPC for her boundless passion for and support of #FOAMed, for her innovation in education, and for her dedication to making you and me better clinicians and educators.  Thank you, T-Chan. Altered Mental Status Powered by #FOAMed -- Tim Horeczko, MD, MSCR, FACEP, FAAP  

Intranasal medications, if understood and employed properly, are a great choice to avoid and IV or as a bridge until IV access is obtained.  Learn the strengths and limits of intranasal fentanyl, midazolam, ketamine, and dexmedetomidine. Pain Management in Children Traditionally, “brutaine”. Goal: the “ouchless ED”.  Two main barriers in pain treatment in children: 1. We consistently under-recognize children’s pain.  We may not detect the typical behaviors that children exhibit when they are in pain, especially in the pre-verbal child: crankiness or fussiness; changes in appetite or sleep; decreased activity; or physiologic findings such as dull eyes, flushed skin, rapid breathing, or sweating.2. We under-treat pain in children.  This is mostly from an old culture of misunderstanding or fear of overdose. Four Components to Successful Pain Management and Intranasal Medication Administration Right drug, right dose, right patient, right timing Right Drug – Not every medication is easily amenable to intranasal administration.  We can use intranasal drugs for analgesia, for anxiolysis, for seizures – but not all drugs used for those purposes will perform well – or at all – via the IN route. Right Dose – Dosing with IN meds will vary considerably from the IV route.  Rule of thumb:  the IN dose is 2-3 times the IV dose. Right Patient – Is this patient and family appropriate for “just taking the edge off”?  What is the level of anxiety in the room?  How is the child relating to the parent, usually it’s the mother there.  What else is going on in that clinical snapshot as you walk in? Right Timing – Mostly IV and IN onset times are very similar.  Notable exception:  intranasal midazolam may take 10-15 minutes to take effect – something to keep in mind when you plan your procedure. Intranasal Medications bypass first-pass metabolism, and a portion of the drug is delivered into the CSF immediately via the nose-brain pathway. Ideal Volume for Intranasal Medication: 0.25 to 0.3 mL per naris Absolute maximum: 1 mL per naris (but expect some run-off) Preload the device with 0.1 mL solution for dead space Administer intranasal medications in the sniffing position.   Lie the patient flat with occiput posterior, put patient in the sniffing position, seat the mucosal atomizing device cushion in the naris, aim toward the pinna of the ear, and shoot fast – you have to push the drug as fast as you can to atomize the solution.  Intranasal Fentanyl Safe, effective at 2 mcg/kg.  Most commonly stocked concentration of fentanyl is 50 mcg/mL.  A 40-kg-child will reach the maximum volume possible for administration (40 kg x 2 mcg/kg = 80 mcg; at 50 mcg/mL – that makes 1.6 mL – if we divide the dose, it’s not ideal, but is still under our maximum of under 1 mL per naris.)  You graduate from intranasal fentanyl in elementary school. Sufentanil for adults (half the volume of fentanyl) – 0.5 mcg/kg, which can be repeated as needed.  Intranasal Midazolam Intranasal Midazolam or versed for anxiolysis is dosed at 0.3 mg/kg (up to 0.5 mg/kg for procedural sedation) Here, another practicality weighs in.  The IV preparation for midazolam is 5 mg/5 mL – this a very dilute solution.  You need to use the 5 mg/mL concentration to have any success with intransal midazolam because of the volume needed for the right effect. A 20-kg-child will near the maximum volume for intranasal midazolam (0.3 mg/kg is 6 mg, at 5 mg/ml, 1.2 mL, or 036 mL per naris).  Kindergarten graduation is when to drop the intranasal midazolam. Intranasal Ketamine The IV dose for ketamine for pain control is 0.15 to 0.3 mg/kg, usually as an infusion over an hour.  The intranasal dose of ketamine for pain control is 1 mg/kg.Low-dose ketamine may be used for pain control as an adjunct and opioid-sparing agent. Intranasal Dexmedetomidine Dexmedetomidine is an alpha-2 receptor agonist, a smarter clonidine.  Clonidine is also an alpha-2 agonist, and it can cause a marked decrease in blood pressure with some mild sedation.  Dexmedetomidine targets receptors in the CNS and spinal cord, and so it provides deep sedation, with very minimal blood pressure effects.  It induces a sleep-like state.  In fact, EEGs done under dex show the same pattern as seen in stage II sleep.  Dex is safe, if titrated, and does not depress airway reflexes or respiration. Dose is 2.5 mcg/kg IN, and can add another 1 mcg/kg if needed. The downside is that it can last 30 minutes or more, but it may be a good choice for an abdominal ultrasound or CT head in unruly toddlers. Before You Go:  The “Semmelweiss reflex”. Selected References Weisman SJ, Bersnstein B, Schechter NL. Consequences of Inadequate Analgesia During Painful Procedures in Children. Biol Neonate. 2000 Feb;77(2):69-82. Anand KJ, Scalzo FM. Can adverse neonatal experiences alter brain development and subsequent behavior? Expert Opin Drug Deliv. 2008 Oct;5(10):1159-68. doi: 10.1517/17425247.5.10.1159 . Wu H, Hu K, Jiang X. From nose to brain: understanding transport capacity and transport rate of drugs. J Opioid Manag. 2012 Jul-Aug;8(4):237-41. doi: 10.5055/jom.2012.0121. Stephen R, Lingenfelter E, Broadwater-Hollifield C, Madsen T. Intranasal sufentanil provides adequate analgesia for emergency department patients with extremity injuries.

Tina concentrates on the details of ADHD medications and invites your attention to the following: Non-pharmacological therapy behavioural therapy Stimulants methylphenidate amphetamines Non-stimulants atomoxetine clonidine other antidepressants and antipsychotics (to be covered in future episodes)   The post ADHD 2: medications appeared first on Family Pharm Podcast.

This podcast reviews the randomized double-blind placebo-controlled trial reported by Boekhout et al. that evaluates venlafaxine and clonidine for the treatment of hot flashes in women with breast cancer.

Buy Clonidine Without Prescription, Well this is the first episode of A Saudi Life that I record after my return to Saudi Arabia. This is a quick and short episode as I am busy settling in and starting the next step in my life, Clonidine blogs. Buy no prescription Clonidine online, Also I need to […]